AU2005303536A1 - Leucine-rich repeat (LRR) motif containing proteins - Google Patents
Leucine-rich repeat (LRR) motif containing proteins Download PDFInfo
- Publication number
- AU2005303536A1 AU2005303536A1 AU2005303536A AU2005303536A AU2005303536A1 AU 2005303536 A1 AU2005303536 A1 AU 2005303536A1 AU 2005303536 A AU2005303536 A AU 2005303536A AU 2005303536 A AU2005303536 A AU 2005303536A AU 2005303536 A1 AU2005303536 A1 AU 2005303536A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- polypeptide
- nucleic acid
- disease
- insp168
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 187
- 102000004169 proteins and genes Human genes 0.000 title claims description 106
- 210000004901 leucine-rich repeat Anatomy 0.000 title claims description 76
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 title claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 475
- 229920001184 polypeptide Polymers 0.000 claims description 452
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 452
- 150000007523 nucleic acids Chemical class 0.000 claims description 198
- 102000039446 nucleic acids Human genes 0.000 claims description 188
- 108020004707 nucleic acids Proteins 0.000 claims description 188
- 238000000034 method Methods 0.000 claims description 176
- 210000004027 cell Anatomy 0.000 claims description 172
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 144
- 201000010099 disease Diseases 0.000 claims description 118
- 150000001875 compounds Chemical class 0.000 claims description 115
- 230000014509 gene expression Effects 0.000 claims description 84
- 239000012634 fragment Substances 0.000 claims description 70
- 230000000694 effects Effects 0.000 claims description 69
- 239000013598 vector Substances 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 53
- 239000003446 ligand Substances 0.000 claims description 47
- 206010029113 Neovascularisation Diseases 0.000 claims description 43
- 230000027455 binding Effects 0.000 claims description 41
- 238000009739 binding Methods 0.000 claims description 41
- 239000000523 sample Substances 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 39
- 210000001519 tissue Anatomy 0.000 claims description 35
- 206010012289 Dementia Diseases 0.000 claims description 32
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 208000006011 Stroke Diseases 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 230000006870 function Effects 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 26
- 108020001507 fusion proteins Proteins 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 26
- 239000005557 antagonist Substances 0.000 claims description 25
- 230000001225 therapeutic effect Effects 0.000 claims description 24
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 23
- 239000000556 agonist Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 22
- 238000012216 screening Methods 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 238000003745 diagnosis Methods 0.000 claims description 19
- 102000005962 receptors Human genes 0.000 claims description 19
- 108020003175 receptors Proteins 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000001684 chronic effect Effects 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 18
- 210000001525 retina Anatomy 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 17
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 17
- 210000003169 central nervous system Anatomy 0.000 claims description 17
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 16
- 208000010412 Glaucoma Diseases 0.000 claims description 16
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 230000009529 traumatic brain injury Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 14
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 14
- 230000002207 retinal effect Effects 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 208000023105 Huntington disease Diseases 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 208000005264 motor neuron disease Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 11
- 210000001328 optic nerve Anatomy 0.000 claims description 10
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 208000005598 Angioid Streaks Diseases 0.000 claims description 8
- 208000002691 Choroiditis Diseases 0.000 claims description 8
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 8
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 8
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
- 201000002832 Lewy body dementia Diseases 0.000 claims description 8
- 208000001344 Macular Edema Diseases 0.000 claims description 8
- 208000026072 Motor neurone disease Diseases 0.000 claims description 8
- 208000021957 Ocular injury Diseases 0.000 claims description 8
- 206010033799 Paralysis Diseases 0.000 claims description 8
- 206010033892 Paraplegia Diseases 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 8
- 206010034010 Parkinsonism Diseases 0.000 claims description 8
- 208000003971 Posterior uveitis Diseases 0.000 claims description 8
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 8
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 8
- 201000007737 Retinal degeneration Diseases 0.000 claims description 8
- 206010038848 Retinal detachment Diseases 0.000 claims description 8
- 201000000582 Retinoblastoma Diseases 0.000 claims description 8
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 8
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 8
- 206010046851 Uveitis Diseases 0.000 claims description 8
- 201000004810 Vascular dementia Diseases 0.000 claims description 8
- 206010054880 Vascular insufficiency Diseases 0.000 claims description 8
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 8
- 208000029028 brain injury Diseases 0.000 claims description 8
- 210000003161 choroid Anatomy 0.000 claims description 8
- 201000010206 cystoid macular edema Diseases 0.000 claims description 8
- 201000011190 diabetic macular edema Diseases 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 201000004614 iritis Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 8
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 8
- 230000007823 neuropathy Effects 0.000 claims description 8
- 201000001119 neuropathy Diseases 0.000 claims description 8
- 208000021090 palsy Diseases 0.000 claims description 8
- 201000007407 panuveitis Diseases 0.000 claims description 8
- 230000035515 penetration Effects 0.000 claims description 8
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 8
- 230000000750 progressive effect Effects 0.000 claims description 8
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 8
- 230000004258 retinal degeneration Effects 0.000 claims description 8
- 230000004264 retinal detachment Effects 0.000 claims description 8
- 208000032253 retinal ischemia Diseases 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- 208000020431 spinal cord injury Diseases 0.000 claims description 8
- 230000000542 thalamic effect Effects 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 208000019553 vascular disease Diseases 0.000 claims description 8
- 208000023577 vascular insufficiency disease Diseases 0.000 claims description 8
- 208000020564 Eye injury Diseases 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 7
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 7
- 239000002853 nucleic acid probe Substances 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 239000013068 control sample Substances 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000013610 patient sample Substances 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 99
- 108020004414 DNA Proteins 0.000 description 85
- 238000003752 polymerase chain reaction Methods 0.000 description 79
- 239000013615 primer Substances 0.000 description 67
- 235000001014 amino acid Nutrition 0.000 description 56
- 150000001413 amino acids Chemical class 0.000 description 55
- 239000002299 complementary DNA Substances 0.000 description 50
- 108091026890 Coding region Proteins 0.000 description 42
- 239000013612 plasmid Substances 0.000 description 42
- 238000003556 assay Methods 0.000 description 39
- -1 adhesion molecules Proteins 0.000 description 37
- 239000000047 product Substances 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 32
- 239000002773 nucleotide Substances 0.000 description 31
- 238000010367 cloning Methods 0.000 description 30
- 239000000872 buffer Substances 0.000 description 29
- 238000000746 purification Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 210000003050 axon Anatomy 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 102100033288 Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 1 Human genes 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 101710178358 Peptidoglycan-associated lipoprotein Proteins 0.000 description 20
- 101710189920 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Proteins 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- SQEHCNOBYLQFTG-UHFFFAOYSA-M lithium;thiophene-2-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CS1 SQEHCNOBYLQFTG-UHFFFAOYSA-M 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 108010067306 Fibronectins Proteins 0.000 description 17
- 102000016359 Fibronectins Human genes 0.000 description 17
- 108010077641 Nogo Proteins Proteins 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000009396 hybridization Methods 0.000 description 17
- 230000004048 modification Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 17
- 238000007792 addition Methods 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 238000012163 sequencing technique Methods 0.000 description 16
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- 102000010410 Nogo Proteins Human genes 0.000 description 15
- 108700026244 Open Reading Frames Proteins 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 102000005781 Nogo Receptor Human genes 0.000 description 14
- 108020003872 Nogo receptor Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000012300 Sequence Analysis Methods 0.000 description 13
- 230000003321 amplification Effects 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 230000002068 genetic effect Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 10
- 239000011543 agarose gel Substances 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 230000005937 nuclear translocation Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000956 olfactory bulb Anatomy 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000008223 sterile water Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 102000002090 Fibronectin type III Human genes 0.000 description 7
- 108050009401 Fibronectin type III Proteins 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 102000006386 Myelin Proteins Human genes 0.000 description 7
- 108010083674 Myelin Proteins Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000004520 electroporation Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 235000014304 histidine Nutrition 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 210000005012 myelin Anatomy 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 102000000568 rho-Associated Kinases Human genes 0.000 description 7
- 108010041788 rho-Associated Kinases Proteins 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 6
- 102000053642 Catalytic RNA Human genes 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000001130 astrocyte Anatomy 0.000 description 6
- 230000003376 axonal effect Effects 0.000 description 6
- 230000008827 biological function Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003959 neuroinflammation Effects 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 108091092562 ribozyme Proteins 0.000 description 6
- 210000003594 spinal ganglia Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000007877 drug screening Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 4
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 150000003862 amino acid derivatives Chemical class 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000020 growth cone Anatomy 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 210000002804 pyramidal tract Anatomy 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000007423 screening assay Methods 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 3
- 102100029727 Enteropeptidase Human genes 0.000 description 3
- 108010013369 Enteropeptidase Proteins 0.000 description 3
- 108050001049 Extracellular proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- NIKBMHGRNAPJFW-IUCAKERBSA-N His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 NIKBMHGRNAPJFW-IUCAKERBSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 3
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000008049 TAE buffer Substances 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002594 corticospinal effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 208000030883 malignant astrocytoma Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000017511 neuron migration Effects 0.000 description 3
- 230000009689 neuronal regeneration Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- SMWADGDVGCZIGK-AXDSSHIGSA-N (2s)-5-phenylpyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)CCC1C1=CC=CC=C1 SMWADGDVGCZIGK-AXDSSHIGSA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- DXJZITDUDUPINW-WHFBIAKZSA-N Gln-Asn Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O DXJZITDUDUPINW-WHFBIAKZSA-N 0.000 description 2
- SSHIXEILTLPAQT-WHFBIAKZSA-N Gln-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSHIXEILTLPAQT-WHFBIAKZSA-N 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 101100027996 Mus musculus Omg gene Proteins 0.000 description 2
- 102000010803 Netrins Human genes 0.000 description 2
- 108010063605 Netrins Proteins 0.000 description 2
- 102100023206 Neuromodulin Human genes 0.000 description 2
- 101710144282 Neuromodulin Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000004590 Peripherins Human genes 0.000 description 2
- 108010003081 Peripherins Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 description 2
- 102000006437 Proprotein Convertases Human genes 0.000 description 2
- 108010044159 Proprotein Convertases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 102100040756 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 101800001364 Slit homolog 2 protein C-product Proteins 0.000 description 2
- 102400000463 Slit homolog 2 protein C-product Human genes 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000023105 myelination Effects 0.000 description 2
- 230000003988 neural development Effects 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000003977 optic chiasm Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000005047 peripherin Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000005871 repellent Substances 0.000 description 2
- 230000002940 repellent Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 101150024653 61 gene Proteins 0.000 description 1
- 101150026651 63 gene Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101150094949 APRT gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- QCTFKEJEIMPOLW-JURCDPSOSA-N Ala-Ile-Phe Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCTFKEJEIMPOLW-JURCDPSOSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- UFOBYROTHHYVGW-CIUDSAMLSA-N Cys-Cys-His Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O UFOBYROTHHYVGW-CIUDSAMLSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- DZLNHFMRPBPULJ-GSVOUGTGSA-N D-thioproline Chemical compound OC(=O)[C@H]1CSCN1 DZLNHFMRPBPULJ-GSVOUGTGSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- PHZYLYASFWHLHJ-FXQIFTODSA-N Gln-Asn-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PHZYLYASFWHLHJ-FXQIFTODSA-N 0.000 description 1
- JNENSVNAUWONEZ-GUBZILKMSA-N Gln-Lys-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JNENSVNAUWONEZ-GUBZILKMSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 1
- XMBSYZWANAQXEV-QWRGUYRKSA-N Glu-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-QWRGUYRKSA-N 0.000 description 1
- CHDWDBPJOZVZSE-KKUMJFAQSA-N Glu-Phe-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O CHDWDBPJOZVZSE-KKUMJFAQSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- SWSVTNGMKBDTBM-DCAQKATOSA-N His-Gln-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SWSVTNGMKBDTBM-DCAQKATOSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- ZSKJIISDJXJQPV-BZSNNMDCSA-N His-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 ZSKJIISDJXJQPV-BZSNNMDCSA-N 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000959111 Homo sapiens Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Proteins 0.000 description 1
- 101000650694 Homo sapiens Roundabout homolog 1 Proteins 0.000 description 1
- 101000650697 Homo sapiens Roundabout homolog 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- 101710088756 Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 1 Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- ZWBCVBHKXHPCEI-BVSLBCMMSA-N Met-Phe-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N ZWBCVBHKXHPCEI-BVSLBCMMSA-N 0.000 description 1
- VSJAPSMRFYUOKS-IUCAKERBSA-N Met-Pro-Gly Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O VSJAPSMRFYUOKS-IUCAKERBSA-N 0.000 description 1
- UYDDNEYNGGSTDW-OYDLWJJNSA-N Met-Trp-Trp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N UYDDNEYNGGSTDW-OYDLWJJNSA-N 0.000 description 1
- 102000003843 Metalloendopeptidases Human genes 0.000 description 1
- 108090000131 Metalloendopeptidases Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 1
- 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- IPVPGAADZXRZSH-RNXOBYDBSA-N Phe-Tyr-Trp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O IPVPGAADZXRZSH-RNXOBYDBSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100027702 Roundabout homolog 1 Human genes 0.000 description 1
- 102100027739 Roundabout homolog 2 Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 1
- 102100023978 Signal transducer and activator of transcription 2 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 1
- 101710133576 Slit homolog 2 protein Proteins 0.000 description 1
- 101800001135 Slit homolog 2 protein N-product Proteins 0.000 description 1
- 102400000462 Slit homolog 2 protein N-product Human genes 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000239110 Staphylococcus virus K Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- ZAGPDPNPWYPEIR-SRVKXCTJSA-N Tyr-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O ZAGPDPNPWYPEIR-SRVKXCTJSA-N 0.000 description 1
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
- BMPPMAOOKQJYIP-WMZOPIPTSA-N Tyr-Trp Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)C1=CC=C(O)C=C1 BMPPMAOOKQJYIP-WMZOPIPTSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009537 cortical lesion Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 101150077062 pal gene Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004491 retinal development Effects 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Description
WO 2006/051333 PCT/GB2005/004390 LEUCINE-RICH REPEAT (LRR) MOTIF CONTAINING PROTEINS This invention relates to proteins, termed INSP168, INSP168-SV1, INSPI49 and INSP169, herein identified as leucine-rich repeat (LRR) motif containing proteins, and to the use of these proteins and nucleic acid sequences from the encoding gene in 5 the diagnosis, prevention and treatment of disease. All publications, patents and patent applications cited herein are incorporated in full by reference. BACKGROUND The process of drug discovery is presently undergoing a fundamental revolution as the 10 era of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences. 15 As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed. Various institutions and commercial organisations are examining sequence data as 20 they become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery. Introduction to Secreted Proteins 25 The ability of cells to make and secrete extracellular proteins is central to many biological processes. Enzymes, growth factors, extracellular matrix proteins and signalling molecules are all secreted by cells. This is through fusion of a secretory vesicle with the plasma membrane. In most cases, but not all, proteins are directed to the endoplasmic reticulum and into secretory vesicles by a signal peptide. Signal peptides 30 are cis-acting sequences that affect the transport of polypeptide chains from the WO 2006/051333 PCT/GB2005/004390 2 cytoplasm to a membrane bound compartment such as a secretory vesicle. Polypeptides that are targeted to the secretory vesicles are either secreted into the extracellular matrix or are retained in the plasma membrane. The polypeptides that are retained in the plasma membrane will have one or more transmembrane domains. Examples of signal peptide 5 containing proteins that play a central role in the functioning of a cell are cytokines, hormones, extracellular matrix proteins, adhesion molecules, receptors, proteases, and growth and differentiation factors. Introduction to PAL The photoreceptor-associated leucine-rich repeat (LRR) protein (abbreviated to PAL) 10 is a membrane glycoprotein that is specifically expressed in the photoreceptor cells of the retina (Gomi et al., J. Neuroscience, 2000, 20(9):3206-3213). Sequencing of the PAL gene revealed that the PAL protein contains an LRR motif, an Ig C2-like domain and a fibronectin type III-like domain, all within its extracellular region. The LRR domain of PAL contains five contiguous LRRs. This combination of 15 the three types of domain described above was identified as a new class of transmembrane protein, although some previously known proteins contain two of these three domains (e.g. Trk and NCAM) (Gomi et al., J. Neuroscience, 2000, 20(9):3206-3213). The abundance of PAL mRNA was observed to increase over the time course of 20 development of the rat retina. Northern blotting experiments revealed that the PAL mRNA was specific to the photoreceptor cells within the retina. Western blotting and immunoprecipitation experiments with a PAL-specific polyclonal antibody showed that PAL forms a strong homodimer structure that is resistant to SDS and high temperature (Gomi et al., J. Neuroscience, 2000, 20(9):3206-3213). 25 A human homolog of PAL was also identified and was mapped to chromosome 10q23.2-23.
3 by fluorescence in situ hybridisation (FISH). On the basis of experiments carried out on rat retinal cells, it was postulated that PAL may act as a receptor for a certain trophic factor or for an adhesion molecule participating in morphogenesis. The human- PAL protein was therefore considered to be a potential 30 candidate disease gene for inherited retinal disorders (Gomi et al., J. Neuroscience, 2000, 20(9):3206-3213).
WO 2006/051333 PCT/GB2005/004390 3 Other known retina-specific genes include rhodopsin, transducin, cGMP-gated ion channels, peripherin/rds and rom-1. Among these, a number of causative genes for inherited diseases of the retina have been identified. For example, mutations in rhodopsin or peripherin/rds contribute to autosomal dominant retinitis pigmentosa. 5 Introduction to the fibronectin type 3 domains Fibronectin Type III (FnIII) protein domains are formed by 80-100 amino acids included in several multimodular proteins, mostly associated to extracellular matrix such as tenascins (Joester A and Faissner A, Matrix Biol. 2001, 20:13-22), or Titins (Skeie GO, Cell Mol Life Sci. 2000, 57:1570-6) or to receptor proteins such as insulin receptor 10 protein family (Marino-Buslje C et al., FEBS Lett. 1998, 441:331-6). Despite remarkably similar tertiary structures, FnIII modules share low sequence homology. Conversely, the sequence homology for the same FnIII module across multiple species is notably higher, suggesting that sequence variability is functionally significant. Amongst the residues that are conserved, Prolines are of particular 15 importance since prevent aggregation in multi-modular proteins containing this domain (Craig D et al., Structure 2004, 12:21-30; Craig D et al., Proc Natl Acad Sci U S A. 2001, 98(10):5590-5; Cota E et al., J Mol Biol. 2001, 305:1185-94; Cota E et al., J Mol Biol. 2000, 302:713-25; Steward A et al., J Mol Biol. 2002, 318:935-40). The paradigm of this protein module is human Fibronectin, a 2386-amino acid 20 glycoprotein of the extracellular matrix containing several protein modules, usually categorized in three types: FnI, FnII, and FnIII (or Fl, F2, or F3; Potts JR and Campbell ID, Matrix Biol. 1996, 15:313-20). Fibronectin circulates in a soluble form in the plasma and is also found in an insoluble, multimeric form within the extracellular matrix at appropriate sites. The formation and the degradation of these 25 insoluble fibrils is a dynamic, cell-dependent process that is mediated by a series of events involving the actin cytoskeleton and integrin receptors. Fibronectin fibrils can bind the surfaces of mammalian and bacterial cells and various molecules including collagen, fibrin, heparin, DNA, and actin. Fibronectin is involved in cell adhesion/contractility/motility, opsonization, wound healing, and formation of fibrotic 30 aggregates. For example, in certain chronic inflammatory diseases, including asthma, the loss of this regulation gives rise either to excess or to inappropriate fibronectin WO 2006/051333 PCT/GB2005/004390 4 deposition that parallels the development of tissue fibrosis (Hocking DC, Chest. 2002, 122(6 Suppl):275S-278S). Finally, isolated fibronectin domains of extracellular matrix proteins, that can be generated physiologically by limited proteolysis or mechanical stress of the 5 fibronectin fibers, can modulate various biological and physiological responses, such as the neuronal regeneration, hippocampal learning and synaptic plasticity (Meiners S and Mercado ML, Mol Neurobiol. 2003, 27:177-96; Strekalova T et al., Mol Cell Neurosci. 2002, 21:173-87), osteoblast adhesion, proliferation and differentiation (Kim TI et al., Biotechnol Lett. 2003, 25:2007-11), tissue degradation, inflammation 10 and tumor progression (Labat-Robert J, Ageing Res Rev. 2004, 3:233-47). Fragments or splicing variants of FnIII domain-containing proteins may become target for antibodies and other proteins blocking them having important therapeutic or diagnostic applications, such as cancer (Ebbinghaus C et al., Curr Pharm Des. 2004, 10:1537-49), inflammatory arthritis (Barilla ML and Carsons SE, Semin Arthritis 15 Rheum. 2000, 29:252-65), or organ transplantation (Coito AJ et al., Dev Immunol. 2000;7:239-48). Introduction to the leucine-rich repeat (LRR) motif The LRR motif is a relatively short motif of around 22-28 residues, and is found in a variety of cytoplasmic, membrane and extracellular proteins. Proteins containing LRRs 20 are associated with a very wide range of biological functions, although all are thought to be involved in protein-protein interaction or cell adhesion. The LRR motif is a repetitive motif made up of several copies of the sequence LxxLxxLxLxxNxLxxL xxxxFxx. LRRs are often flanked by cysteine-rich repeat regions, an N-terminal LRR motif or a leucine rich repeat C-terminal domain (LRRCT). 25 Introduction to Immunoglobulin Domains The immunoglobulin (Ig) domain is a well characterised domain present in hundreds of proteins of varying functions. The basic Ig domain structure is a tetramer of two light chains and two heavy chains linked by disulphide bonds. Immunoglobulin domain-containing cell surface recognition molecules have been shown to play a role 30 in diverse physiological functions, many of which can play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and as WO 2006/051333 PCT/GB2005/004390 5 such identification of novel immunoglobulin domain-containing cell surface recognition molecules is highly relevant as they may play a role in many diseases, particularly inflammatory disease, oncology, and cardiovascular disease. Immunoglobulin domain-containing cell surface recognition molecules are involved 5 in a range of biological processes, including: embryogenesis, maintenance of tissue integrity, leukocyte extravasation/inflammation, oncogenesis, angiogenesis, bone resorption, neurological dysfunction, thrombogenesis, and invasion/adherence of bacterial pathogens to the host cell. The detailed characterisation of the structure and function of several immunoglobulin 10 domain containing cell surface recognition molecule families has led to active programs by a number of pharmaceutical companies to develop modulators for use in the treatment of diseases involving inflammation, oncology, neurology, immunology and cardiovascular function. Inmunoglobulin domain containing cell surface recognition molecules are involved in virtually every aspect of biology from 15 embryogenesis to apoptosis. They are essential to the structural integrity and homeostatic functioning of most tissues. It is therefore not surprising that defects in immunoglobulin domain containing cell surface recognition molecules cause disease and that many diseases involve modulation of immunoglobulin domain containing cell surface recognition molecule function. 20 Immunoglobulin domain-containing cell surface recognition molecules are thus known to play a role in diverse physiological functions, many of which can play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and as such identification of novel immunoglobulin domain-containing cell surface recognition molecules is highly relevant as they may play a role in many 25 diseases, particularly immunology, inflammatory disease, oncology, cardiovascular disease, central nervous system disorders and infection. In summary, cell surface recognition molecules, including those containing LRRs, Ig domains or fibronectin type 3 domains, have been shown to play a role in diverse physiological functions, many of which can play a role in disease processes. Alteration 30 of their activity is a means to alter the disease phenotype and as such identification of novel adhesion molecules is highly relevant as they may play a role in many diseases, particularly inflammatory disease, oncology, cardiovascular disease and bacterial WO 2006/051333 PCT/GB2005/004390 6 infection. The identification of further retina-specific cell surface recognition molecules, including paralogs of the human PAL protein (which will contain LRRs, Ig domains and fibronectin type 3 domains) is of great importance in the ongoing investigation of retinal developments and retinal pathologies. Their identification will 5 allow the development of new methods for the treatment and diagnosis of retinal diseases and disorders. Accordingly, there remains a need for the identification of such proteins to enable new drugs to be developed for the treatment and prevention of human disease. THE INVENTION 10 The invention is based on the discovery that the INSP168, INSP168-SV1, INSP149 and INSP169 proteins are splice variants of a leucine-rich repeat (LRR) motif containing sequence with similarity to PAL (SwissProt Acc. Code PALPHUMAN) and to a nogo receptor homolog (SwissProt Acc. Code Q6X814). In particular, the invention is based on the finding that polypeptides of the present 15 invention are PAL-like and/or nogo-receptor like molecules. In a first aspect of the invention, there is provided a polypeptide, which polypeptide: (i) comprises the amino acid sequence as recited in SEQ ID NO:2 (mature INSP168); (ii) is a fragment thereof which functions as a biologically active 20 polypeptide and/or has an antigenic determinant in common with the polypeptides of (i); or (iii) is a functional equivalent of (i) or (ii). A polypeptide according to part (i) of the first aspect of the invention may comprise the amino acid sequence as recited in SEQ ID NO:4 (mature INSP149), SEQ ID NO:8 25 (mature INSP168-SV1) or SEQ ID NO:10 (mature INSP169). Although the Applicant does not wish to be bound by this theory, it is postulated that the first 19 amino acids of the INSP168, INSP168-SV1, INSP149 and INSP169 proteins forms a signal peptide, as shown in the schematic representation below: MHLFACLCIVLSFLEGVGCLCPSQCTCDYHGRNDGSGSR... 30 Thus, a polypeptide according to part (i) of the first aspect of the invention may WO 2006/051333 PCT/GB2005/004390 7 comprise the amino acid sequence as recited in SEQ ID NO:30 (full length INSP168), SEQ ID NO:32 (full length INSP149), SEQ ID NO:34 (full length INSP168-SV1), SEQ ID NO:36 (full length INSP169) and SEQ ID NO:67 (INSPl69 cloned extracellular region). 5 A polypeptide according to part (i) of the first aspect of the invention may comprise the extracellular portion of the amino acid sequence as recited in SEQ ID NO:4 (mature INSP149) or SEQ ID NO:10 (mature INSP169). Thus, a polypeptide according to part (i) of the first aspect of the invention may comprise the amino acid sequence as recited in SEQ ID NO:6 (INSP149 extracellular region) or SEQ ID 10 NO:12 (INSP 169 extracellular region). A polypeptide according to part (i) of the first aspect of the invention may comprise the amino acid sequence as recited in SEQ ID NO:67 (INSP169 cloned extracellular region). The cloned extracellular region of INSP169 (SEQ ID NO:67) differs from the predicted extracellular region of INSP169 at amino acid 524 (see Example 7 and Figure 8). 15 The INSP168, INSP168-SV1, INSP149 and INSP169 proteins each contain a leucine rich repeat motif. The amino acid sequence of the leucine-rich repeat motif present in the INSP168, INSP168-SV1, INSP149 and INSP169 proteins is recited in SEQ ID NO:14. Accordingly, preferred fragments of the INSP168, INSP168-SV1, INSP149 and INSP169 proteins are fragments that comprise or consist of the amino acid 20 sequence as recited in SEQ ID NO:14 (LRR motif). A polypeptide according to part (i) of the first aspect of the invention may comprise the amino acid sequence as recited in SEQ ID NO:2 (mature INSP168), SEQ ID NO:4 (mature INSP149), SEQ ID NO:6 (1NSP149 extracellular region), SEQ ID NO:8 (mature INSP168-SV1), SEQ ID NO:10 (mature INSP169), SEQ ID NO:12 25 (INSP169 extracellular region), SEQ ID NO:14 (LRR motif), SEQ ID NO:30 (full length INSP168), SEQ ID NO:32 (full length INSP149), SEQ ID NO:34 (full length INSP168-SV1), SEQ ID NO:36 (full length INSP169) or SEQ ID NO:67 (INSP169 cloned extracellular region) and a histidine tag. Preferably the histidine tag is located at the C-terminus of the polypeptide. Preferably the histidine tag comprises between 1 30 and 10 histidine residues (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 residues). More preferably, the histidine tag comprises 6 residues. Thus, a polypeptide according to part (i) of the first aspect of the invention may comprise the amino acid sequence as recited in SEQ ID NO:16 (his tag mature INSP168), SEQ ID NO:18 (his tag mature INSP149), SEQ WO 2006/051333 PCT/GB2005/004390 8 ID NO:20 (his tag INSP149 extracellular region), SEQ ID NO:22 (his tag mature INSP168-SV1), SEQ ID NO:24 (his tag mature INSP169), SEQ ID NO:26 (his tag INSP169 extracellular region), SEQ ID NO:28 (his tag LRR motif), SEQ ID NO:38 (his tag full length INSP168), SEQ ID NO:40 (his tag full length INSP149), SEQ ID 5 NO:42 (his tag full length INSP168-SV1) or SEQ ID NO:44 (his tag full length INSP169). Thus, the first aspect of the present invention provides a polypeptide which comprises or consists of the amino acid sequence as recited in SEQ ID NO:2 (mature INSP168), SEQ ID NO:4 (mature INSP149), SEQ ID NO:6 (INSP149 extracellular region), SEQ 10 ID NO:8 (mature INSPl68-SV1), SEQ ID NO:10 (mature INSP169), SEQ ID NO:12 (INSP 169 extracellular region), SEQ ID NO:14 (LRR motif), SEQ ID NO:16 (his tag mature INSP168), SEQ ID NO:18 (his tag mature INSP149), SEQ ID NO:20 (his tag INSP149 extracellular region), SEQ ID NO:22 (his tag mature INSP168-SV1), SEQ ID NO:24 (his tag mature INSP169), SEQ ID NO:26 (his tag INSP169 extracellular 15 region), SEQ ID NO:28 (his tag LRR motif), SEQ ID NO:30 (full length INSP168), SEQ ID NO:32 (full length INSP149), SEQ ID NO:34 (full length INSP168-SVI), SEQ ID NO:36 (full length INSP169), SEQ ID NO:38 (his tag full length INSP168), SEQ ID NO:40 (his tag full length INSP149), SEQ ID NO:42 (his tag full length INSP168-SV1), SEQ ID NO:44 (his tag full length INSP169), or SEQ ID NO:67 20 (INSP169 cloned extracellular region). The first aspect of the present invention also provides a polypeptide which is a fragment of such a polypeptide and which functions as a biologically active polypeptide and/or has an antigenic determinant in common with such a polypeptide or which is a functional equivalent of such a polypeptide. The terms "the INSP168 polypeptides" and "an INSP168 polypeptide" as used herein 25 include polypeptides comprising or consisting of the amino acid sequence as recited in SEQ ID NO:2 (mature INSP168), such as polypeptides comprising or consisting of the amino acid sequence as recited in SEQ ID NO:4 (mature INSP149), SEQ ID NO:6 (INSP149 extracellular region), SEQ ID NO:8 (mature INSP168-SV1), SEQ ID NO:10 (mature INSP169), SEQ ID NO:12 (INSP169 extracellular region), SEQ ID 30 NO:16 (his tag mature INSP168), SEQ ID NO:18 (his tag mature INSP149), SEQ ID NO:20 (his tag INSP149 extracellular region), SEQ ID NO:22 (his tag mature INSP168-SV1), SEQ ID NO:24 (his tag mature INSP169), SEQ ID NO:26 (his tag INSP169 extracellular region), SEQ ID NO:30 (full length INSP168), SEQ ID NO:32 WO 2006/051333 PCT/GB2005/004390 9 (full length INSP149), SEQ ID NO:34 (full length INSP168-SV1), SEQ ID NO:36 (full length INSP169), SEQ ID NO:38 (his tag full length INSP168), SEQ ID NO:40 (his tag full length INSP149), SEQ ID NO:42 (his tag full length INSP168-SV1), SEQ ID NO:44 (his tag full length 1NSP169) or SEQ ID NO:67 (INSP169 cloned 5 extracellular region). INSP149, INSP168 and INSP169 were a set of predictions representing splice variants of a leucine rich repeat-containing sequence with similarity to the retina specific protein PAL. INSP149 was a prediction for a 595 amino acid (1785 bp) ORF encoded in 5 exons. 10 INSP168 was a prediction for a 197 amino acid (591 bp) ORF encoded in 3 exons. INSP169 was a prediction for a 679 amino acid (2037 bp) ORF encoded in 4 exons. INSP149 and INSP169 were predicted to be type I transmembrane proteins comprising a leucine-rich repeat motif, an immunoglobulin domain and a fibronectin type 3 domain. The INSP169 polypeptide is a splice variant of the INSP149 15 polypeptide that is identical to INSP149 except for the longer final exon, which subsumes the final two exons of INSP149. The longer sequence encoded by INSP169 has the same domain organisation as INSP149 but has a low complexity insert between the Ig and FN III domains. INSP168 was essentially a truncated splice variant of INSP149 and INSP169 and was predicted to represent a secreted protein. 20 The INSP168 polypeptide is a splice variant of the INSP149 polypeptide that comprises a stop codon at the start of its third exon. As a result of this truncation in the third exon, the INSP168 polypeptide lacks the transmembrane region found in exon 5 of INSP149. All 3 of the predictions contained 4 leucine rich repeat regions in the N-terminal portion (SEQ ID NO:14). INSP149 and INSP169 also contained an 25 immunoglobulin domain and a fibronectin type III domain in the predicted extracellular regions. An alignment of the 3 predicted amino acid sequences is shown in Figure 1. As noted above, a signal peptide was predicted spanning from residues 1 to 19. The open reading frame (ORF) of the INSP168 prediction has been cloned using a 30 pair of PCR primers (see Figures 2 and 3). The primer pair was tested on selected cDNA libraries derived from brain and retina and on brain and eye cDNA templates using Platinum@ Taq DNA Polymerase High Fidelity (HiFi). PCR products were cloned and sequenced and a clone was identified, amplified from brain cDNA, which WO 2006/051333 PCT/GB2005/004390 10 contained the expected INSP168 ORF. A second clone was identified, also amplified from brain cDNA, which contained a splice variant of the INSP168 ORF. This clone contained a 32 amino acid insertion towards the 3' end of the INSP168 ORF which represented a new exon 3. The insertion also caused a frameshift such that the new 5 exon 4 contained an extra 6 amino acids compared with the original INSP168 exon 3. This clone was called INSP168-SV1, and is also shown in the Figure 1 alignment. The INSP168 polypeptides are structurally related to the Retinal Specific Protein PAL (SwissProt Acc. Code PALPHUMAN) and to a nogo receptor homolog (SwissProt Acc. Code Q6X814). An amino acid alignment between the INSP168, INSP168-SV1, 10 INSP149 and INSP169 polypeptides and PAL is shown in Figure 5, and the schematic representation of domains is shown in Figure 6. As noted above, the cloned extracellular region of INSP169 (SEQ ID NO:67) differs from the predicted extracellular region of INSP169 at amino acid 524 (see Example 7 and Figure 8). 15 PAL may be implicated in diseases of the retina, retinal pigment epithelium (RPE), and choroids (see for example JP2001128686). These include ocular neovascularization, ocular inflammation and retinal degenerations. Specific examples of these disease states include diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal 20 neovascularization, subretinal neovascularization; rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, 25 cystoid macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, and retinal artery occlusion, and, neovascularization due to penetration of the eye or ocular injury. Additional relevant diseases include the neuropathies, such as Leber's, idiopathic, drug-induced, optic, and ischemic neropathies. 30 Nogo receptor-like proteins could be major inhibitors of CNS neuronal regeneration (Schwab ME. Curr Opin Neurobiol. 2004 Feb;14(l):118-24; Teng et al. J Neurochem. 2004 May;89(4):801-6). Animals treated with antibodies targeted to Nogo-A always WO 2006/051333 PCT/GB2005/004390 11 showed a higher degree of recovery in various behavioural tests (e.g. IN-1 Fab' fragments or new purified IgGs against Nogo-A). In addition, a Nogo-66 antagonistic peptide (NEP 1-40) effected significantly axon growth of the corticospinal tract and improved functional recovery in rats inflicted with mid-thoracic spinal cord 5 hemisections. Subcutaneous administration of NEP1-40 in spinal cord lesioned animals resulted in extensive growth of corticospinal axons, sprouting of serotonergic fibres, synapse formation and enhanced locomotor recovery. Soluble Fc fusion proteins of the Nogo receptor subunit NgR, which blocks Nogo, significantly reduce the inhibitory activity of myelin. Similar results were obtained after Nogo gene 10 deletions and blockade of the downstream messengers Rho-A and ROCK in animal models. The leucine-rich repeat domain of SLIT proteins is sufficient for guiding both axon projection and neuronal migration in vitro (the LRR region of SLIT is structurally related to the LRR region of INSP168, INSP168-SV1, INSP149 and INSP169). As 15 such, the LRR region of INSP168, INSP168-SV1, INSP149 and INSP169 or fragments containing the LRR region might be useful in the treatment of the diseases listed herein. SLIT-like proteins are thought to act as molecular guidance cue in cellular migration, and function appears to be mediated by interaction with roundabaout homolog receptors (bind ROBOl and ROB02 with high affinity). 20 During neural development, SLIT is involved in axonal navigation at the ventral midline of the neural tube and projection of axons to different regions. In spinal chord development, SLIT may play a role in guiding commissural axons once they reached the floor plate by modulating the response to netrin. SLIT may be implicated in spinal chord midline post-crossing axon repulsion. In the developing visual system, SLIT 25 appears to function as repellent for retinal ganglion axons by providing a repulsion that directs these axons along their appropriate paths prior to, and after passage through, the optic chiasm. In vitro, SLIT collapses and repels retinal ganglion cell growth cones. SLIT seems to play a role in branching and arborization of CNS sensory axons, and in neuronal cell migration. In vitro, Slit homolog 2 protein N 30 product, but not Slit homolog 2 protein C-product, repells olfactory bulb (OB) but not dorsal root ganglia (DRG) axons, induces OB growth cones collapse and induces branching of DRG axons. SLIT seems to be involved in regulating leukocyte migration.
WO 2006/051333 PCT/GB2005/004390 12 INSP168, INSP168-SV1, [NSP149 and INSP169 and other INSP168 polypeptides and/or fragments and functional equivalents thereof (e.g. fragments containing the LRR region) can be useful in the diagnosis and/or treatment of diseases for which other (e.g. above mentioned PAL- and Nogo receptor-like proteins) structurally 5 related proteins demonstrate therapeutic activity. In particular, polypeptides of the invention consisting of and/or comprising of the mature (lacking a signal peptide) forms and/or cleaved forms of INSP168, INSP168 SV1 and/or mature soluble forms of INSP149 and/or INSP169, and/or agonists thereof are useful for the diagnosis and/or treatment of diseases. Preferably, the 10 soluble forms of INSP149 and/or INSP169 consist of the mature extracellular part and/or cleaved fragments of INSP149 and/or INSP169. Antagonists of membrane bound INSP149 and/or INSP169, for example antibodies, are useful for the diagnosis and/or treatment of diseases. The INSP168, INSP168-SV1, INSP149 and INSP169 polypeptides maybe implicated 15 in diseases of the retina, spinal cord injuries (e.g. paraplegia) and neurodegenerative disorders. These include disorders of the central nervous system as well as disorders of the peripheral nervous system. Neurodegenerative disorders include, but are not limited to, brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease (including amyotrophic 20 lateral sclerosis, ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post- traumatic brain injury, and small-vessel cerebrovascular disease. Dementias, such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism, frontotemporal dementias (including Pick's disease), progressive nuclear palsy, corticobasal degeneration, Huntington's 25 disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoffs psychosis, as well as stroke and trauma. In particular, the INSP168, INSP168-SV1, INSP149 and INSP169 polypeptides may be implicated in diseases of the retina, retinal pigment epithelium (RPE), and choroids; ocular neovascularization, ocular inflammation and retinal degenerations; 30 diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile madular degeneration, retinal neovascularization, subretinal neovascularization; rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting WO 2006/051333 PCT/GB2005/004390 13 following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, retinal artery occlusion, 5 neovascularization due to penetration of the eye or ocular injury, neuropathies; Leber's, idiopathic, drug-induced, optic, and ischemic neropathies; spinal cord injuries, paraplegia, neurodegenerative disorders, disorders of the central nervous system, disorders of the peripheral nervous system, brain injuries, cerebrovascular diseases, Parkinson's disease, corticobasal degeneration, motor neuron disease, 10 amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post- traumatic brain injury, small-vessel cerebrovascular disease, dementias, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinsonism, frontotemporal dementias, Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic 15 degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, Korsakoffs psychosis, stroke and trauma. Neuro-inflammation is a common feature of several neurological diseases, traumatic situations (at central or peripheral level), stroke (brain, heart, renal), or infectious diseases (mediated by viral agents such as HIV or bacterial agents such as 20 meningitis), leading to an excessive inflammatory response in central nervous system. Many stimuli, originated by neuronal or oligodendroglial cells suffering due to these various conditions, can trigger neuro-inflammation. In particular, astrocytes can secrete various chemokines and cytokines, inducing a recruitment of additional leukocytes that in their turn will further stimulate astrocytes, leading to an 25 exacerbated response. In chronic neurodegenerative diseases such as multiple sclerosis (MS), spinal muscular atrophies (SMA), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), or amylotrophic lateral sclerosis (ALS), the presence of persistent neuro-inflammation is thought to be involved in the progression of the disease and in the case of AD in the secondary events such as 30 micro-hemorrhagic events (Cacquevel M et al., Curr Drug Targets. 2004, 5: 529-534; Chavarria A et al., Autoimmun Rev. 2004, 3: 251-260; Ambrosini E and Aloisi F, Neurochem Res. 2004, 29: 1017-103 8). Limited axon regeneration and plasticity is central to the pathophysiology of a range WO 2006/051333 PCT/GB2005/004390 14 of neurological disorders, including stroke, head trauma, multiple sclerosis, and neurodegenerative disease. In addition to its role in the pathophysiology of neurological disorders as well as in loss of sight or blindness, nogo-like molecules are implicated in cancer. Without 5 wishing to be bound to this theory, the polypeptides of the present invention are implicated in cancer through EGFR inhibition. Preferably, the cancer is lung cancer. The biological properties of the 1NSP168, INSP168-SV1, INSP149 and INSP169 polypeptides related to neuroprotection, maintenance of axonal integrity, myelination and re-/generation of myelin producing cells, can be tested in various assays involving 10 cell lines. For example, the neuroimmunodulatory effects of a compound can be evaluated in U373, a human astroglioma cell line in which the nuclear translocation of specific regulatory proteins involved in cytokine/chemokine expression can be quantified (Le Roy E et al., J Virol. 1999, 73: 6582-9; Jin Y et al., J Infect Dis. 1998, 177: 1629-1638; Acevedo-Duncan M et al., Cell Growth Differ. 1995, 6: 1353-1365). 15 A series of assays has been performed, and have indicated that the addition of a culture medium containing INSP168 stimulates Stat-2 nuclear translocation in U373 cells. This first series of experiments thus revealed that INSP168 has the capacity to stimulate intracellular signalling.by inducing Stat-2 nuclear translocation in U373 cells. Activation of Stat proteins signaling is known to be associated with 20 immunomodulation and eventually cell proliferation (Pfitzner E et al., Curr Pharm Des. 2004, 10: 2839-2850). A polypeptide according to the first aspect of the invention may thus function as an activator of cell proliferation, as a neuromodulator (neuroimmunomodulator), as a modulator of the inflammatory response in the CNS, as a regulator of astrocyte 25 proliferation or as a regulator of axon projection, neuronal migration or leukocyte recruitment or migration. Preferably, the activity of a polypeptide of the present invention can be confirmed in at least one of the following assays: a) in the maintenance of neuronal cell survival, for example in the regeneration 30 of injured adult neurons, or WO 2006/051333 PCT/GB2005/004390 15 b) in the modulation of neurite growth in animal models of spinal cord injury (Fouad et al., Brain.Res.Rev. 2001, Vol. 36, pp.204-212; Bareyre et al., J.Neurosci. 2002, Vol.22, pp.7097-7110; GrandPre et al. Nature 2002, Vol.417, pp.547-551; Li and Strittmatter, J.Neurosci. 2003, Vol.23, pp.4219 5 4227; Liebscher et al. Ann.Neurol. 2005, Vol.58, pp.706-719), for example in the modulation of myelin inhibition of neurite outgrowth, and other CNS lesions such as cortical lesions or cerebral ischemia induced by middle cerebral artery occlusion (Yu Hsuan Teng and Luen Tang, Journal of Neurochemistry 2005, Vol.94, pp.865-874; Papadopoulos et al. Ann.Neurol. 10 2002, Vol.51, pp.433-441; Emerick et al. J.Neurosci. 2003, Vol.23, pp.4826 4830), or c) in the modulation of axonal growth of many neuron types, for example of corticospinal tract (CST) axons, corticofugal, retinal, superior cervical ganglion, spinal or hippocampal neurons, dorsal column axons, for example, 15 in the modulation of axonal plasticity of unlesioned cortical neurons (with enhanced behavioural recovery), or d) in the translocation of Stat2 as described in Example 6, or e) in the up-regulation of growth factors or growth-related proteins, for example of Brain-derived neurotrophic factor (BDNF), Vascular Endothelial Growth 20 Factor (VEGF) and/or Growth-associated protein 43 (GAP-43), or f) in the regeneration of nerve fibers, for example of raphespinal, rubrospinal or corticospinal fibers, or in the regeneration of injured optic nerve fibers (for example in an optic nerve crush model), or g) in the improvement of locomotor function, or 25 h) in the regulation of secretases, for example of p-secretases, or i) in the modulation of apoptosis, for example by modulating pro-apoptotic proteins of the Bcl-2 family and/or mitochondrial proteins, or j) in the modulation of Rho and/or Rho-associated kinase (ROCK), or k) in the modulation of p-secretases, for example of BACEl activity, and/or 30 amyloid-p peptide generation and/or formation of amyloid plaques, or WO 2006/051333 PCT/GB2005/004390 16 1) in the regulation of ocular dominance (OD) plasticity, or m) in the modulation of the phosphorylation of the epidermal growth factor receptor (EGFR), or n) in the stabilization of neural circuitry, or 5 o) in the modulation of dendritic plasticity. As regards the Nogo receptor (NgR), the myelin inhibitory proteins Nogo, myelin associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (Omgp) all bind to the extracellular leucine-rich repeat (LRR) domain of NgR. Thus, polypeptides of the invention comprising and/or consisting of the LRR domain can at 10 least display activity in one of the above-mentioned assays. Polypeptides of the invention consisting of and/or comprising of the mature (lacking a signal peptide) fonns and/or cleaved forms of INSP168, INSP168-SV1 and/or mature soluble forms of INSP149 and/or INSP169, and/or agonists thereof are preferably used in the above-mentioned assays. Preferably, the soluble forms of INSP149 and/or 15 INSP169 consist of the mature extracellular part and/or cleaved fragments of INSP149 and/or INSP169. Alternatively, antagonists of membrane bound INSP149 and/or INSP169, for example antibodies, can be used in the above-mentioned assays. Preferred epitopes of the polypeptides of the present invention can be detected by "affinity fingerprinting" as described in Schimmele and Plickthun (Journal of 20 Molecular Biology 2005, Vol.352, Issue 1, pp.229-241). Polypeptides of the present invention may undergo cleavage by metalloendopeptidase and/or proprotein convertases such as zinc metalloproteinases, N-Arginine dibasic (NDR) convertase or subtilisin-like proprotein convertases. NDR cleavage sites and PCSK cleavage sites have been detected in the polypeptides of the present invention. 25 The skilled artisan will appreciate that such resulting cleaved fragments of the polypeptides of the present invention can be used for the diagnosis and/or treatment of diseases. Cleavage of membrane-bound INSP149 and/or INSP169 can yield soluble N- and C- terminal fragments useful on their own or as components of fusion proteins such as Fc fusion. 30 A NDR cleavage site has been detected in the full length polypeptides of the present invention at position 70-72 (RRI), located after the first LRR motif. Surprisingly, PCSK cleavage sites have been detected at position 207-209 (KRT) of full length WO 2006/051333 PCT/GB2005/004390 17 INSP168-SV1 and at positions 439-441 (KRS) and 449-451 (KRN) of full length membrane bound INSP169. Interestingly, the PCSK cleavage site in INSP168-SV1 is located just after the LRR motifs and for INSP169 between the LRR motifs and the fibronectin domain. The polypeptides of the present invention also encompass the 5 resulting cleaved N-fragments and/or C-fragments or mature forms thereof. Preferably, the resulting cleaved fragments are soluble fragments. Preferably, the resulting fragments consist of: (i) the first 208 amino acids of INSP168-SV1 or the mature form thereof, or (ii) the first 440 amino acids of INSP169 or the mature form thereof, or 10 (iii) the first 450 amino acids of INSP169 or the mature form thereof. This aspect of the invention also includes fusion proteins that incorporate the polypeptides of the first aspect of the invention. An "antigenic determinant" of the present invention may be a part of a polypeptide of the present invention, which binds to an antibody-combining site or to a T-cell 15 receptor (TCR). Alternatively, an "antigenic determinant" may be a site on the surface of a polypeptide of the present invention to which a single antibody molecule binds. Generally an antigen has several or many different antigenic determinants and reacts with antibodies of many different specificities. Preferably, the antibody is immunospecific to a polypeptide of the invention. Preferably, the antibody is 20 immunospecific to a polypeptide of the invention, which is not part of a fusion protein. Preferably, the antibody is immunospecific to INSP168, INSP168-SV1, INSP149 or INSP169 or a fragment thereof. Antigenic determinants usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three dimensional structural characteristics, as well as 25 specific charge characteristics. Preferably, the "antigenic determinant" refers to a particular chemical group on a polypeptide of the present invention that is antigenic, i.e. that elicit a specific immune response. The polypeptides AA104038 (SEQ ID NO:68), XP_853150 (SEQ ID NO:69) and ENSCAFP00000016927 (SEQ ID NO:70), and their encoding nucleic acid sequences 30 are specifically excluded from the scope of this invention. In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention.
WO 2006/051333 PCT/GB2005/004390 18 The term "purified nucleic acid molecule" preferably refers to a nucleic acid molecule of the invention that (1) has been separated from at least about 50 percent of proteins, lipids, carbohydrates, or other materials with which it is naturally found when total nucleic acid is isolated from the source cells, (2) is not linked to all or a portion of a 5 polynucleotide to which the "purified nucleic acid molecule" is linked in nature, (3) is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecule(s) or other contaminants that are found in its 10 natural environment that would interfere with its use in polypeptide production or its therapeutic, diagnostic, prophylactic or research use. In a preferred embodiment, genomic DNA are specifically excluded from the scope of the invention. Preferably, genomic DNA larger than 10 kbp (kilo base pairs), 50 kbp, 100 kbp, 150 kbp, 200 kbp, 250 kbp or 300 kbp are specifically excluded from the scope of the invention. 15 Preferably, the "purified nucleic acid molecule" consists of cDNA only. Preferably, the purified nucleic acid molecule comprises or consists of the nucleic acid sequence as recited in the nucleic acid sequence as recited in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO: 9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID 20 NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41 , SEQ ID NO: 43 and/or SEQ ID NO:66, or is a redundant equivalent or fragment of those sequences. Preferably, the purified nucleic acid molecule consists of the nucleic acid sequence as 25 recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO: 43 and/or SEQ ID NO:66, or is a redundant equivalent 30 or fragment of those sequences. In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention. High stringency hybridisation conditions are defined WO 2006/051333 PCT/GB2005/004390 19 as overnight incubation at 42*C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/mil denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 5 65'C. In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention. In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention. 10 In a sixth aspect, the invention provides a ligand which binds specifically to, and which preferably inhibits the activity of, a leucine-rich repeat motif containing polypeptide of the first aspect of the invention. In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the 15 invention or to regulate the activity of a polypeptide of the first aspect of the invention. Such compounds may be identified using the assays and screening methods disclosed herein. A compound of the seventh aspect of the invention may either increase (agonise) or 20 decrease (antagonise) the level of expression of the gene or the activity of the polypeptide. Importantly, the identification of the domain organisation and function of the INSP168, INSP168-SV1, INSP149 and INSP169 polypeptides allows for the design of screening methods capable of identifying compounds that are effective in the 25 treatment and/or diagnosis of disease. Ligands and compounds according to the sixth and seventh aspects of the invention may be identified using such methods. These methods are included as aspects of the present invention. Using these methods, it will now be possible to identify inhibitors or antagonists of INSP168, INSP168-SV1, INSP149 and INSP169, such as, for example, monoclonal antibodies, which may be 30 of use in modulating INSP168, INSP168-SV1, INSP149 and INSP169 activity in vivo in clinical applications. Such compounds are likely to be useful in counteracting the WO 2006/051333 PCT/GB2005/004390 20 biological activity of the INSP168, INSP168-SV1, INSP149 and INSP169 polypeptides. Another aspect of this invention resides in the use of an INSP168, INSP168-SV1, INSP149 or INSPI69 gene or polypeptide as a target for the screening of candidate 5 drug modulators, particularly candidate drugs active against leucine-rich repeat (LRR) motif containing protein related disorders. A further aspect of this invention resides in methods of screening of compounds for therapy of leucine-rich repeat (LRR) motif containing protein related disorders, comprising determining the ability of a compound to bind to an INSP168, INSP168 10 SV1, INSPI49 or INSPI69 gene or polypeptide, or a fragment thereof. A further aspect of this invention resides in methods of screening of compounds for therapy of leucine-rich repeat (LRR) motif containing protein related disorders, comprising testing for modulation of the activity of an INSP168, INSP168-SV1, INSP149 or INSP169 gene or polypeptide, or a fragment thereof 15 In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis of diseases in which 20 leucine-rich repeat motif containing proteins are implicated. Such diseases include, but are not limited to, diseases of the retina, retinal pigment epithelium (RPE), and choroids; ocular neovascularization, ocular inflammation and retinal degenerations; diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization; 25 rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, retinitis pigmentosa, retinal 30 vein occlusion, proliferative vitreoretinopathy, angioid streak, retinal artery occlusion, neovascularization due to penetration of the eye or ocular injury, neuropathies; Leber's, idiopathic, drug-induced, optic, and ischemic neropathies; spinal cord WO 2006/051333 PCT/GB2005/004390 21 injuries, paraplegia, neurodegenerative disorders, disorders of the central nervous system, disorders of the peripheral nervous system, brain injuries, cerebrovascular diseases, Parkinson's disease, corticobasal degeneration, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, 5 post-stroke, post- traumatic brain injury, small-vessel cerebrovascular disease, dementias, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinsonism, frontotemporal dementias, Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with 10 dementia, Korsakoffs psychosis, stroke and trauma. The moieties of the first, second, third, fourth, fifth, sixth or seventh aspect of the invention may also be used in the manufacture of a medicament for the treatment of such diseases. In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, 15 comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out in vitro. Similar 20 methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease. A preferred method for detecting polypeptides of the first aspect of the invention 25 comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex. A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid 30 hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic WO 2006/051333 PCT/GB2005/004390 22 treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease. Preferably, the disease diagnosed by a method of the ninth aspect of the invention is a disease in which leucine-rich repeat motif containing polypeptides are implicated, as 5 described above. In a tenth aspect, the invention provides for the use of the polypeptide of the first aspect of the invention as an activator of cell proliferation, as a neuromodulator (neuroimmunomodulator), as a modulator of the inflammatory response in the CNS, as a regulator of astrocyte proliferation or as a regulator of axon projection, neuronal 10 migration or leukocyte recruitment or migration. INSP168 and INSP168-SVI, or truncated fonns of INSP149 and INSP169 (for example, lacking the transmembrane region) could be used as recombinant soluble antagonists of the endogenous activity of INSP149 and INSP169. Another suitable use of the INSP168 polypeptides is use in the screening of drug compounds that are effective against the diseases and conditions 15 in which the INSP 168 polypeptides are implicated. In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the 20 sixth aspect of the invention, or a compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier. In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth 25 aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease in which leucine-rich repeat motif containing polypeptides are implicated. Such diseases include those described above in connection with the eighth aspect of the invention. 30 In a thirteenth aspect, the invention provides a method of treating a disease in a patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or WO 2006/051333 PCT/GB2005/004390 23 a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention. For diseases in which the expression of a natural gene encoding a polypeptide of the 5 first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, host cell, ligand or compound administered to the patient should be an agonist. Conversely, for diseases in which the expression of the natural gene or activity of the 10 polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, host cell, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes and ligands, such as antibodies. 15 In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a polypeptide of the first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such 20 a disease. As used herein, "functional equivalent" refers to a protein or nucleic acid molecule that possesses functional or structural characteristics that are substantially similar to a polypeptide or nucleic acid molecule of the present invention. A functional equivalent of a protein may contain modifications depending on the necessity of such 25 modifications for the perfonnance of a specific function. The term "functional equivalent" is intended to include the fragments, mutants, hybrids, variants, analogs, or chemical derivatives of a molecule. Preferably, the "functional equivalent" may be a protein or nucleic acid molecule that exhibits any one or more of the functional activities of the polypeptides of the present 30 invention. Preferably, the "functional equivalent" may be a protein or nucleic acid molecule that displays substantially similar activity compared with INSP168, INSP168-SV1, WO 2006/051333 PCT/GB2005/004390 24 INSP149 or INSP169 or fragments thereof in a suitable assay for the measurement of biological activity or function. Preferably, the "functional equivalent" may be a protein or nucleic acid molecule that displays identical or higher activity compared with INSP168, INSP168-SV1, INSP149 or INSP169 or fragments thereof in a 5 suitable assay for the measurement of biological activity or function. Preferably, the "functional equivalent" may be a protein or nucleic acid molecule that displays 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 100% or more activity compared with INSP168, INSP168-SV1, INSP149 or INSP169 or fragments thereof in a suitable assay for the measurement of biological activity or function. 10 Preferably, the "functional equivalent" may be a protein or polypeptide capable of exhibiting a substantially similar in vivo or in vitro activity as the polypeptides of the invention. Preferably, the "functional equivalent" may be a protein or polypeptide capable of interacting with other cellular or extracellular molecules in a manner substantially similar to the way in which the corresponding portion of the 15 polypeptides of the invention would. For example, a "functional equivalent" would be able, in an immunoassay, to diminish the binding of an antibody to the corresponding peptide (i.e., the peptide the amino acid sequence of which was modified to achieve the "functional equivalent") of the polypeptide of the invention, or to the polypeptide of the invention itself, where the antibody was raised against the corresponding 20 peptide of the polypeptide of the invention. An equimolar concentration of the functional equivalent will diminish the aforesaid binding of the corresponding peptide by at least about 5%, preferably between about 5% and 10%, more preferably between about 10% and 25%, even more preferably between about 25% and 50%, and most preferably between about 40% and 50%. 25 For example, functional equivalents can be fully functional or can lack function in one or more activities. Thus, in the present invention, variations can affect the function, for example, of the activities of the polypeptide that reflect its possession of a leucine rich repeat (LRR) motif. A summary of standard techniques and procedures which may be employed in order 30 to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and it is not intended that this WO 2006/051333 PCT/GB2005/004390 25 terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of the appended claims. Standard abbreviations for nucleotides and amino acids are used in this specification. The practice of the present invention will employ, unless otherwise indicated, 5 conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art. Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N 10 Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods in Enzymology series (Academic 15 Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of Experimental 20 Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986). As used herein, the term "polypeptide" includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins). 25 The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is employed for purification of the mature polypeptide sequence. 30 As noted above, the polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences which may contain secretory or leader sequences, WO 2006/051333 PCT/GB2005/004390 26 pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene 5 glycol). Polypeptides of the invention are useful on their own, as components of fusion proteins such as Fc fusion, and/or in combination with another agent. Preferably, the Fc fusion comprises the mature form of INSP168, the mature form of INSP168-SV1 or the mature form of the extracellular part of INSP169 or INSP149. 10 Preferably the agent is selected among interferon-beta, soluble NgR (e.g. Nogo-66), antibodies targeted to NgR, antibodies targeted to myelin inhibitors (e.g. Nogo, MAG or Omgp), CXCL1O, agonists of serotonin receptors (e.g. 5-HT1A/2A/7), LIF, EGFR blockers such as Erlotinib, and/or methylprednisolone. In a further preferred embodiment, a polypeptide of the invention, that may comprise 15 a sequence having at least 85% of homology with INSP168, INSP168-SV1, INSP149 or INSP 169, is a fusion protein. These fusion proteins can be obtained by cloning a polynucleotide encoding a polypeptide comprising a sequence having at least 85% of homology with INSP168, INSP168-SV1, INSP149 or INSP169 in frame to the coding sequences for a 20 heterologous protein sequence. The term "heterologous", when used herein, is intended to designate any polypeptide other than a human INSP168, INSP168-SV1, INSP149 or INSP169 polypeptide. Examples of heterologous sequences, that can be comprised in the fusion proteins either at the N- or C-terminus, include: extracellular domains of membrane-bound 25 protein, immunoglobulin constant regions (Fc regions), multimerization domains, domains of extracellular proteins, signal sequences, export sequences, and sequences allowing purification by affinity chromatography. Many of these heterologous sequences are commercially available in expression plasmids since these sequences are commonly included in fusion proteins in order to 30 provide additional properties without significantly impairing the specific biological activity of the protein fused to them (Terpe K, 2003, Appl Microbiol Biotechnol, 60:523-33). Examples of such additional properties are a longer lasting half-life in WO 2006/051333 PCT/GB2005/004390 27 body fluids, the extracellular localization, or an easier purification procedure as allowed by the a stretch of Histidines forming the so-called "histidine tag" (Gentz et al. 1989, Proc Natl Acad Sci USA, 86:821-4) or by the "HA" tag, an epitope derived from the influenza hemagglutinin protein (Wilson et al. 1994, Cell, 37:767-78). If 5 needed, the heterologous sequence can be eliminated by a proteolytic cleavage, for example by inserting a proteolytic cleavage site between the protein and the heterologous sequence, and exposing the purified fusion protein to the appropriate protease. These features are of particular importance for the fusion proteins since they facilitate their production and use in the preparation of pharmaceutical compositions. 10 For example, the INSP168, INSP168-SV1, INSP149 or INSP169 polypeptide may be purified by means of a hexa-histidine peptide fused at the C-terminus of INSP168, INSP168-SVl, INSP149 or INSP169. When the fusion protein comprises an immunoglobulin region, the fusion may be direct, or via a short linker peptide which can be as short as 1 to 3 amino acid residues in length or longer, for example, 13 15 amino acid residues in length. Said linker may be a tripeptide of the sequence E-F-M (Glu-Phe-Met), for example, or a 13-amino acid linker sequence comprising Glu-Phe Gly-Ala-Gly-Leu-Val-Leu-Gly-Gly-Gln-Phe-Met (SEQ ID NO:71) introduced between the sequence of the substances'of the invention and the immunoglobulin sequence. The resulting fusion protein has improved properties, such as an extended 20 residence time in body fluids (i.e. an increased half-life), increased specific activity, increased expression level, or the purification of the fusion protein is facilitated. In a preferred embodiment, the protein is fused to the constant region of an Ig molecule. Preferably, it is fused to heavy chain regions, like the CH2 and CH3 domains of human IgG1, for example. Other isoforms of Ig molecules are also 25 suitable for the generation of fusion proteins according to the present invention, such as isoforns IgG2 or IgG4, or other Ig classes, like IgM or IgA, for example. Fusion proteins may be monomeric or multimeric, hetero- or homomultimeric. In a further preferred embodiment, the functional derivative comprises at least one moiety attached to one or more functional groups, which occur as one or more side 30 chains on the amino acid residues. Preferably, the moiety is a polyethylene (PEG) moiety. PEGylation may be carried out by known methods, such as the ones described in W099/55377, for example. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, WO 2006/051333 PCT/GB2005/004390 28 modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for 5 instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulphide bond 10 formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. 15 Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention. 20 The modifications that occur in a polypeptide often will be a function of how the polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, 25 glycosylation patterns vary between different types of host cell. The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a 30 combination of these methods. The functionally-equivalent polyp-eptides of the first aspect of the invention may be polypeptides that are homologous to the INSP 168 polypeptides. Two polypeptides are WO 2006/051333 PCT/GB2005/004390 29 said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" 5 indicates that, at any particular position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence 10 Data, Part 1, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Preferably, percentage identity, as referred to herein, is as determined using BLAST version 2.1.3 using the default parameters specified by the 15 NCBI (the National Center for Biotechnology Information; http://www.ncbi.nlm.nih.gov/) [Blosum 62 matrix; gap open penalty=1 1 and gap extension penalty= 1]. Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the 20 polypeptides are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the INSP168 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded 25 by the genetic code. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any 30 combination. Especially preferred are silent substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions. Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent WO 2006/051333 PCT/GB2005/004390 30 group. In accordance with the present invention, any substitution should be preferably a "conservative" or "safe" substitution, which is commonly defined a substitution introducing an amino acids having sufficiently similar chemical properties (e.g. a 5 basic, positively charged amino acid should be replaced by another basic, positively charged amino acid), in order to preserve the structure and the biological function of the molecule. The literature provide many models on which the selection of conservative amino acids substitutions can be performed on the basis of statistical and physico-chemical 10 studies on the sequence and/or the structure of proteins (Rogov SI and Nekrasov AN, 2001). Protein design experiments have shown that the use of specific subsets of amino acids can produce foldable and active proteins, helping in the classification of amino acid "synonymous" substitutions which can be more easily accommodated in protein structure, and which can be used to detect functional and structural homologs 15 and paralogs (Murphy LR et al., 2000). The groups of synonymous amino acids and the groups of more preferred synonymous amino acids are shown in Table 1. Specific, non-conservative mutations can be also introduced in the polypeptides of the invention with different purposes. Mutations reducing the affinity of the protein may increase its ability to be reused and recycled, potentially increasing its therapeutic 20 potency (Robinson CR, 2002). Immunogenic epitopes eventually present in the polypeptides of the invention can be exploited for developing vaccines (Stevanovic S, 2002), or eliminated by modifying their sequence following known methods for selecting mutations for increasing protein stability, and correcting them (van den Burg B and Eijsink V, 2002; WO 02/05146, WO 00/34317, WO 98/52976). 25 Preferred alternative, synonymous groups for amino acids derivatives included in peptide mimetics are those defined in Table 2. A non-exhaustive list of amino acid derivatives also include aminoisobutyric acid (Aib), hydroxyproline (Hyp), 1,2,3,4 tetrahydro-isoquinoline-3-COOH, indoline-2carboxylic acid, 4-difluoro-proline, L thiazolidine-4-carboxylic acid, L-homoproline, 3,4-dehydro-proline, 3,4-dihydroxy 30 phenylalanine, cyclohexyl-glycine, and phenylglycine. By "amino acid derivative" is intended an amino acid or amino acid-like chemical entity other than one of the 20 genetically encoded naturally occurring amino acids. In WO 2006/051333 PCT/GB2005/004390 31 particular, the amino acid derivative may contain substituted or non-substituted, linear, branched, or cyclic alkyl moieties, and may include one or more heteroatoms. The amino acid derivatives can be made de novo or obtained from commercial sources (Calbiochem-Novabiochem AG, Switzerland; Bachem, USA). 5 Various methodologies for incorporating unnatural amino acids derivatives into proteins, using both in vitro and in vivo translation systems, to probe and/or improve protein structure and function are disclosed in the literature (Dougherty DA, 2000). Techniques for the synthesis and the development of peptide mimetics, as well as non-peptide mimetics, are also well known in the art (Golebiowski A et al., 2001; 10 Hruby VJ and Balse PM, 2000; Sawyer TK, in "Structure Based Drug Design", edited by Veerapandian P, Marcel Dekker Inc., pg. 557-663, 1997). Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group. Typically, greater than 80% identity between two polypeptides is considered to be an 15 indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the 1NSP168 polypeptides, or with active fragments thereof, of greater than 80%. More preferred polypeptides have degrees of identity of greater than 90%, 95%, 98% or 99%, respectively. 20 The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome Threader technology that forms one aspect of the search tools used to generate the Biopendium search database may be used (see PCT application published as WO 01/69507) to identify polypeptides of 25 presently-unknown function which, while having low sequence identity as compared to the INSP168 polypeptides, are predicted to be cell surface recognition molecules by virtue of sharing significant structural homology with the INSP168 polypeptide sequences. By "significant structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty 30 of 10% and above. The polypeptides of the first aspect of the invention also include fragments of the INSP168 polypeptides and fragments of the functional equivalents of these WO 2006/051333 PCT/GB2005/004390 32 polypeptides, provided that those fragments retain the biological activity of the INSP168 polypeptides, or have an antigenic determinant in common with these polypeptides. As used herein, the term "fragment" refers to a polypeptide having an amino acid 5 sequence that is the same as part, but not all, of the amino acid sequence of the INSP168 polypeptides or one of their functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant. 10 Nucleic acids according to the invention are preferably 10-2000 nucleotides in length, preferably 100-1750 nucleotides, preferably 500-1500, preferably 600-1200, preferably 750-1000 nucleotides in length. Polypeptides according to the invention are preferably 10-700 amino acids in length, preferably 50-600, preferably 100-500, preferably 200-400, preferably 300-375 amino acids in length. 15 Fragments of the full length 1NSP168, INSP168-SV1, 1NSP149 and INSP169 exon polypeptides and the INSP168, INSP168-SV1, INSP149 and 1NSP169 polypeptides may consist of combinations of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 of neighbouring exon sequences in the 1NSP168, 1NSP168-SV1, 1NSP149 and INSP169 polypeptides, respectively. 20 Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre- and/or pro- polypeptide 25 region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus of the fragment. However, several fragments may be comprised within a single larger polypeptide. The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such 30 as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity WO 2006/051333 PCT/GB2005/004390 33 chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related 5 polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')2 and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention. By "substantially greater affinity" we mean that there is a measurable increase in the 10 affinity for a polypeptide of the invention as compared with the affinity for known cell-surface receptors. Preferably, the affinity is at least 1.5-fold, 2-fold, 5-fold 10-fold, 100-fold, 10 3 -fold, 10 4 -fold, 10 5 -fold, 10 6 -fold or greater for a polypeptide of the invention than for known cell surface recognition molecules. 15 Preferably, there is a measurable increase in the affinity for a polypeptide of the invention as compared with known leucine-rich repeat (LRR) motif containing proteins. If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. 20 The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. 25 Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography. Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, 30 Kohler_ G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985).
WO 2006/051333 PCT/GB2005/004390 34 Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc. Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding 5 the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in appropriate vectors. Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu et al., Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)), may also be of use. 10 The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones et al., Nature, 321, 522 (1986); Verhoeyen et al., Science, 239, 1534 (1988); Kabat et al., J. Immunol., 147, 1709 (1991); Queen et al., Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gorman et al., Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Hodgson et al., Bio/Technology, 9, 421 (1991)). The 15 term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody. The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody. 20 In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen-binding domains, each domain being directed against a different epitope. Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from 25 repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628). 30 Antibodies generated by the above techniques, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these WO 2006/051333 PCT/GB2005/004390 35 applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme. Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequence as recited in SEQ ID NO:2, SEQ ID 5 NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44 and/or SEQ ID NO:67, and functionally equivalent polypeptides. These 10 nucleic acid molecules may be used in the methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25,30,35, 40 or more). The nucleic acid molecules of the invention also include sequences that are 15 complementary to nucleic acid molecules described above (for example, for antisense or probing purposes). Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical 20 synthetic techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the in vitro or in vivo transcription of DNA sequences. 25 The nucleic acid molecules may be double-stranded or single-stranded. Single stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term 30 "PNA", as used herein, refers to an antisense molecule or an anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine WO 2006/051333 PCT/GB2005/004390 36 confers solubility to the composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63). 5 A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:2 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO: 1. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:4 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:3. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:6 may be 10 identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:5. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:8 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:7. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:10 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:9. 15 A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:12 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO: 11. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:14 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:13. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:16 20 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:15. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:18 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:17. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:20 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ 25 ID NO: 19. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:22 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:21. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:24 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:23. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:26 30 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:25. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:28 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:27. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:30 WO 2006/051333 PCT/GB2005/004390 37 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:29. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:32 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:3 1. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:34 5 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:33. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:36 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:35. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:38 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ 10 ID NO:37. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:40 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:39. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:42 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:41. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:44 15 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:43. A nucleic acid molecule which encodes the polypeptide of SEQ ID NO:67 may be identical to the coding sequence of the nucleic acid molecule shown in SEQ ID NO:66. These molecules also may have a different sequence which, as a result of the 20 degeneracy of the genetic code, encodes a polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID 25 NO:44 or SEQ ID NO:67. Such nucleic acid molecules may include, but are not limited to, the coding sequence for the mature polypeptide by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pro-, pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with or without the 30 aforementioned additional coding sequences, together with further additional, non coding sequences, including non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals), ribosome binding and mRNA stability. The nucleic acid molecules may also WO 2006/051333 PCT/GB2005/004390 38 include additional sequences which encode additional amino acids, such as those which provide additional functionalities. The nucleic acid molecules of the second and third aspects of the invention may also encode the fragments or the functional equivalents of the polypeptides and fragments 5 of the first aspect of the invention. Such a nucleic acid molecule may be a naturally occurring variant such as a naturally-occurring allelic variant, or the molecule may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms. 10 Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions or insertions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or 15 insertions. The nucleic acid molecules of the invention can also be engineered, using methods generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic 20 oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth. Nucleic acid molecules which encode a polypeptide of the first aspect of the invention 25 may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a 30 commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and WO 2006/051333 PCT/GB2005/004390 39 purified away from the heterologous protein. The nucleic acid molecules of the invention also include antisense molecules that are partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules 5 (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee et al., 10 Nucleic Acids Res 6, 3073 (1979); Cooney et al., Science 241, 456 (1988); Dervan et al., Science 251, 1360 (1991). The term "hybridization" as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules 15 may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTTO); the concentration of the molecules; use of compounds to increase the rate 20 of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook et al. [supra]). The inhibition of hybridization of a completely complementary molecule to a target molecule may be examined using a hybridization assay, as known in the art (see, for 25 example, Sambrook et al [supra]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511). 30 "Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42'C in a WO 2006/051333 PCT/GB2005/004390 40 solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (p17.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 65*C. Low stringency conditions 5 involve the hybridisation reaction being carried out at 35*C (see Sambrook et al. [supra]). Preferably, the conditions used for hybridization are those of high stringency. Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to nucleic acid molecules encoding 10 the INSP168 polypeptides (such as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO: 44, or SEQ ID NO:67) and nucleic acid molecules that 15 are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to the nucleic acid molecules having the sequence recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID 20 NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43 or SEQ ID NO:66 or a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98% or 99% identical over their entire length to the same are 25 particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the INSP 168 polypeptides. The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the 30 invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed. As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as WO 2006/051333 PCT/GB2005/004390 41 a hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full length cDNAs and genomic clones encoding the INSP168 polypeptides and to isolate cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide. 5 In this regard, the following techniques, among others known in the art, may be utilised and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA 10 polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the 15 Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer). One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INSP168 polypeptides is to probe a genomic or 20 cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel et al. (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are 25 complementary to, nucleic acid sequences from the appropriate encoding gene (such as SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43 or SEQ ID 30 NO:66) are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to, radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the WO 2006/051333 PCT/GB2005/004390 42 ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and screening such sources for related sequences, for example, for additional members of the family, type and/or subtype. 5 In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory 10 elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the MarathonTM technology (Clontech Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly 15 different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR 20 which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991); Nucleic Acids Res. 19:3055 3060). Additionally, one may use PCR, nested primers, and PromoterFinderTM 25 libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences that contain the 5' regions of genes. Use of a 30 randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions. In one embodiment of the invention, the nucleic acid molecules of the present WO 2006/051333 PCT/GB2005/004390 43 invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important step in the confirmatory correlation 5 of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationships between genes 10 and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular genomic region, any 15 sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals. The nucleic acid molecules of the present invention are also valuable for tissue 20 localisation. Such techniques allow the determination of expression patterns of the polypeptide in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of the polypeptide in the organism. In addition, comparative studies of the normal 25 expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature. Gene silencing approaches may also be undertaken to down-regulate endogenous expression of a gene encoding a polypeptide of the invention. RNA interference 30 (RNAi) (Elbashir, SM et al., Nature 2001, 411, 494-498) is one method of sequence specific post-transcriptional gene silencing that may be employed. Short dsRNA oligonucleotides are synthesised in vitro and introduced into a cell. The sequence specific binding of these dsRNA oligonucleotides triggers the degradation of target WO 2006/051333 PCT/GB2005/004390 44 mRNA, reducing or ablating target protein expression. Efficacy of the gene silencing approaches assessed above may be assessed through the measurement of polypeptide expression (for example, by Western blotting), and at the RNA level using TaqMan-based methodologies. 5 The vectors of the present invention comprise nucleic acid molecules of the invention and may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic. The polypeptides of the invention may be prepared in recombinant form by 10 expression of their encoding nucleic acid molecules in vectors contained within a host cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook et al (supra) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto). 15 Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those described in Sambrook et al., (supra). Generally, the encoding gene can be placed under the 20 control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell. Examples of suitable expression systems include, for example, chromosomal, episomal and virus-derived systems, including, for example, vectors derived from: 25 bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. Human artificial 30 chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. The pCR4-TOPO-INSP168, pCR4-TOPO-INSP168-SVl, pEAK12dINSP168-6HIS, WO 2006/051333 PCT/GB2005/004390 45 pENTRINSP168-6HIS, and pDEST12.2_INSP168-6HIS vectors are preferred examples of suitable vectors for use in accordance with this invention. Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression 5 vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation 10 systems can also be employed to produce the polypeptides of the invention. Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al.,[supra]. Particularly suitable methods include calcium phosphate 15 transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection (see Sambrook et al., 1989 [supra]; Ausubel et al., 1991 [supra]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal 20 integration) according to the needs of the system. The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These 25 signals may be endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing. In addition to control sequences, it may be desirable to add regulatory sequences that allow for regulation of the expression of the polypeptide relative to the growth of the 30 host cell. Examples of regulatory sequences are those which cause the expression of a gene to- be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or WO 2006/051333 PCT/GB2005/004390 46 metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers, promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system 5 and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSportlfm plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect 10 cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the 15 sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker. An expression vector is constructed so that the particular nucleic acid coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory 20 sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame. 25 The control sequences and other regulatory sequences may be ligated to the nucleic acid coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site. For long-term, high-yield production of a recombinant polypeptide, stable expression 30 is preferred. For example, cell lines which stably express the polypeptide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may WO 2006/051333 PCT/GB2005/004390 47 be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be 5 proliferated using tissue culture techniques appropriate to the cell type. Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 10 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines. In the baculovirus system, the materials for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA (the "MaxBac" kit). These techniques are generally known to those skilled in the art and 15 are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Particularly suitable host cells for use in this system include insect cells such as Drosophila S2 and Spodoptera Sf9 cells. There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those 20 described in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture have been described by Zenk, Phytochemistry 30, 3861-3863 (1991). In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which 25 contain the transferred gene. Practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables. Examples of particularly preferred bacterial host cells include streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells. 30 Examples of particularly suitable host cells for fungal expression include yeast cells (for example, S. cerevisiae) and Aspergillus cells. Any number of selection systems are known in the art that may be used to recover WO 2006/051333 PCT/GB2005/004390 48 transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes that can be employed in tk- or aprt± cells, respectively. 5 Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to 10 chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art. Although the presence or absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For 15 example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection 20 usually indicates expression of the tandem gene as well. Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for 25 example, fluorescence activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, 30 D.E. et al. (1983) J. Exp. Med, 158, 1211-1216). A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for WO 2006/051333 PCT/GB2005/004390 49 producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide. Alternatively, the sequences encoding the polypeptide of the 5 invention may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); 10 Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH)). Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like. Nucleic acid molecules according to the present invention may also be used to create 15 transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention. 20 The polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid 25 chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during isolation and or purification. Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a 30 nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Examples of such purification-facilitating domains include metal chelating peptides such as histidine-tryptophan modules that allow purification on WO 2006/051333 PCT/GB2005/004390 50 immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San 5 Diego, CA) between the purification domain and the polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity 10 chromatography as described in Porath, J. et al. (1992), Prot. Exp. Purif. 3: 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453). If the polypeptide is to be expressed for use in screening assays, generally it is 15 preferred that it be secreted into the culture medium of the host cell in which it is expressed. In this event, the polypeptides of the invention may be purified from the culture medium may be harvested prior to use in the screening assay, for example using standard protein purification techniques such as gel exclusion chromatography, ion-exchange chromatography or affinity chromatography. Examples of suitable 20 methods of protein purification are provided in the Examples herein. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered. Alternatively, it may be preferred that the polypeptides of the invention be expressed as cell-surface fusion proteins. In this event, the host cells may be harvested prior to 25 use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACs) or immunoaffinity techniques. As indicated above, the present invention also provides novel targets and methods for the screening of drug candidates or leads. These screening methods include binding assays and/or functional assays, and may be performed in vitro, in cell systems or in 30 animals.
WO 2006/051333 PCT/GB2005/004390 51 In this regard, a particular object of this invention resides in the use of an INSP168 polypeptide as a target for screening candidate drugs for treating or preventing disorders in which leucine-rich repeat (LRR) motif containing proteins are implicated. Another object of this invention resides in methods of selecting biologically active 5 compounds, said methods comprising contacting a candidate compound with a 1NSP168 gene or polypeptide, and selecting compounds that bind said gene or polypeptide. A further other object of this invention resides in methods of selecting biologically active compounds, said method comprising contacting a candidate compound with 10 recombinant host cell expressing a INSP 168 polypeptide with a candidate compound, and selecting compounds that bind said INSP168 polypeptide at the surface of said cells and/or that modulate the activity of the INSP 168 polypeptide. A "biologically active" compound denotes any compound having biological activity in a subject, preferably therapeutic activity, more preferably a compound that can be 15 used for treating disorders in which leucine-rich repeat (LRR) motif containing proteins are implicated, or as a lead to develop drugs for treating disorders in which leucine-rich repeat (LRR) motif containing proteins are implicated. A "biologically active" compound preferably is a compound that modulates the activity of a INSP 168 polypeptide. 20 The above methods may be conducted in vitro, using various devices and conditions, including with immobilized reagents, and may further comprise an additional step of assaying the activity of the selected compounds in a model of a disorder in which leucine-rich repeat (LRR) motif containing proteins are implicated, such as an animal model. 25 Binding to a target gene or polypeptide provides an indication as to the ability of the compound to modulate the activity of said target, and thus to affect a pathway leading to disorder in a subject. The determination of binding may be performed by various techniques, such as by labelling of the candidate compound, by competition with a labelled reference ligand, etc. For in vitro binding assays, the polypeptides may be 30 used in essentially pure form, in suspension, immobilized on a support, or expressed in a membrane (intact cell, membrane preparation, liposome, etc.).
WO 2006/051333 PCT/GB2005/004390 52 Modulation of activity includes, without limitation, stimulation of the surface expression of a receptor, and modulation of multimerization of said receptor (e.g., the formation of multimeric complexes with other sub-units), etc. The cells used in the assays may be any recombinant cell (i.e., any cell comprising a recombinant nucleic 5 acid encoding a INSP168 polypeptide) or any cell that expresses an endogenous INSP168 polypeptide. Examples of such cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells (such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include E.coli, Pichia pastoris, Hansenula polymorpha, Schizosaccharomyces pombe, Kluyveronyces or 10 Saccharomyces yeasts, mammalian cell lines (e.g., Vero cells, CHO cells, 3T3 cells, COS cells, etc.) as well as primary or established mammalian cell cultures (e.g., produced from fibroblasts, embryonic cells, epithelial cells, nervous cells, adipocytes, etc.). Preferred selected compounds are agonists of INSP168, i.e., compounds that can bind 15 to INSP 168 and mimic the activity of an endogenous ligand thereof. A further object of this invention resides in a method of selecting biologically active compounds, said method comprising contacting in vitro a test compound with a INSP168 polypeptide according to the present invention and determining the ability of said test compound to modulate the activity of said INSP 168 polypeptide. 20 A further object of this invention resides in a method of selecting biologically active compounds, said method comprising contacting in vitro a test compound with a INSP168 gene according to the present invention and determining the ability of said test compound to modulate the expression of said INSP168 gene, preferably to stimulate expression thereof. 25 In another embodiment, this invention relates to a method of screening, selecting or identifying active compounds, the method comprising contacting a test compound with a recombinant host cell comprising a reporter construct, said reporter construct comprising a reporter gene under the control of a INSP168 gene promoter, and selecting the test compounds that modulate (e.g. stimulate or reduce, preferably 30 stimulate) expression of the reporter gene. The polypeptide of the invention can be used to screen libraries of compounds in any WO 2006/051333 PCT/GB2005/004390 53 of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit (antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which 5 encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention. Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or 10 structural or functional mimetics. For a suitable review of such screening techniques, see Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991). Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, 15 polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented. The polypeptide of the invention that is employed in such a screening technique may 20 be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. In general, such screening procedures may involve using appropriate cells or cell membranes that express the polypeptide that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then 25 compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed. 30 Methods for generating detectable signals in the types of assays described herein will be known to those of skill in the art. A particular example is cotransfecting a construct expressing a polypeptide according to the invention, or a fragment such as the LBD, WO 2006/051333 PCT/GB2005/004390 54 in fusion with the GAL4 DNA binding domain, into a cell together with a reporter plasmid, an example of which is pFR-Luc (Stratagene Europe, Amsterdam, The Netherlands). This particular plasmid contains a synthetic promoter with five tandem repeats of GAL4 binding sites that control the expression of the luciferase gene. When 5 a potential ligand is added to the cells, it will bind the GAL4-polypeptide fusion and induce transcription of the luciferase gene. The level of the luciferase expression can be monitored by its activity using a luminescence reader (see, for example, Lehman et al. JBC 270, 12953, 1995; Pawar et al. JBC, 277, 39243, 2002). A preferred method for identifying an agonist or antagonist compound of a 10 polypeptide of the present invention comprises: (a) contacting a cell expressing on the surface thereof a polypeptide according to the first aspect of the invention, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to 15 permit binding to the polypeptide; and (b) determining whether the compound binds to and activates or inhibits the polypeptide by measuring the level of a signal generated from the interaction of the compound with the polypeptide. A further preferred method for identifying an agonist or antagonist of a polypeptide of 20 the invention comprises: (a) contacting a cell expressing on the surface thereof the polypeptide, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and 25 (b) determining whether the compound binds to and activates or inhibits the polypeptide by comparing the level of a signal generated from the interaction of the compound with the polypeptide with the level of a signal in the absence of the compound. For example, a method such as FRET detection of a ligand bound to the polypeptide 30 in the-presence of peptide co-activators (Norris et al., Science 285, 744, 1999) might be used.
WO 2006/051333 PCT/GB2005/004390 55 In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of labelled or unlabelled ligand for the polypeptide. In another embodiment of the method for identifying agonist or antagonist of a 5 polypeptide of the present invention comprises: determining the inhibition of binding of a ligand to cells which have a polypeptide of the invention on the surface thereof, or to cell membranes containing such a polypeptide, in the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of ligand bound to the 10 polypeptide. A compound capable of causing reduction of binding of a ligand is considered to be an agonist or antagonist. Preferably the ligand is labelled. More particularly, a method of screening for a polypeptide antagonist or agonist compound comprises the steps of: (a) incubating a labelled ligand with a whole cell expressing a polypeptide according 15 to the invention on the cell surface, or a cell membrane containing a polypeptide of the invention, (b) measuring the amount of labelled ligand bound to the whole cell or the cell membrane; (c) adding a candidate compound to a mixture of labelled ligand and the whole cell or 20 the cell membrane of step (a) and allowing the mixture to attain equilibrium; (d) measuring the amount of labelled ligand bound to the whole cell or the cell membrane after step (c); and (e) comparing the difference in the labelled ligand bound in step (b) and (d), such that the compound which causes the reduction in binding in step (d) is considered to be an 25 agonist or antagonist. The polypeptides may be found to modulate a variety of physiological and pathological processes in a dose-dependent manner in the above-described assays. Thus, the "functional equivalents" of the polypeptides of the invention include polypeptides that exhibit any of the same modulatory activities in the above-described 30 assays in a dose-dependent manner. Although the degree of dose-dependent activity need not be identical to that of the polypeptides of the invention, preferably the WO 2006/051333 PCT/GB2005/004390 56 "functional equivalents" will exhibit substantially similar dose-dependence in a given activity assay compared to the polypeptides of the invention. In certain of the embodiments described above, simple binding assays may be used, in which the adherence of a test compound to a surface bearing the polypeptide is 5 detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the 10 presence of any test compound that possesses specific binding affinity for the polypeptide. Persons skilled in the art will be able to devise assays for identifying modulators of a polypeptide of the invention. Of interest in this regard is Lokker NA et al., J. Biol. Chem., 1997, Dec 26;272(52):33037-44, which reports an example of an assay to 15 identify antagonists (in this case neutralizing antibodies). Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using monoclonal or polyclonal antibodies by standard methods known in the art, and this 20 can be used to search for compounds that may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured. Another technique for drug screening which may be used provides for high 25 throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application W084/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising 30 antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.
WO 2006/051333 PCT/GB2005/004390 57 Assay methods that are also included within the terms of the present invention are those that involve the use of the genes and polypeptides of the invention in overexpression or ablation assays. Such assays involve the manipulation of levels of these genes/polypeptides in cells and assessment of the impact of this manipulation 5 event on the physiology of the manipulated cells. For example, such experiments reveal details of signalling and metabolic pathways in which the particular genes/polypeptides are implicated, generate information regarding the identities of polypeptides with which the studied polypeptides interact and provide clues as to methods by which related genes and proteins are regulated. 10 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the polypeptide of interest (see International patent application W084/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and 15 washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be detected using methods that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. The polypeptide of the invention may be used to identify membrane-bound or soluble 20 receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, 25 tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance (supplied by Biacore AB, Uppsala, Sweden) and spectroscopy. Binding assays may be used for the purification and cloning of the receptor, but may also identify agonists and antagonists of the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard 30 methods for conducting screening assays are well understood in the art. In another embodiment, this invention relates to the use of a INSP168, INSP168-SV1, INSP149 or INSP169 polypeptide or fragment thereof, whereby the fragment is preferably a INSP168, 1NSP168-SV1, INSP149 or INSP169 gene-specific fragment, WO 2006/051333 PCT/GB2005/004390 58 for isolating or generating an agonist or stimulator of the INSP168, INSP168-SV1, INSP 149 or INSP 169 polypeptide for the treatment of a disorder, wherein said agonist or stimulator is selected from the group consisting of: 1. a specific antibody or fragment thereof including: a) a chimeric, b) a 5 humanized or c) a fully human antibody, as well as; 2. a bispecific or multispecific antibody, 3. a single chain (e.g. scFv) or 4. single domain antibody, or 5. a peptide- or non-peptide mimetic derived from said antibodies or 10 6. an antibody-mimetic such as a) an anticalin or b) a fibronectin-based binding molecule (e.g. trinectin or adnectin). The generation of peptide- or non-peptide mimetics from antibodies is known in the art (Saragovi et al., 1991 and Saragovi et al., 1992). Anticalins are also known in the art (Vogt et al., 2004). Fibronectin-based binding 15 molecules are described in US6818418 and W02004029224. Furthermore, the test compound may be of various origin, nature and composition, such as any small molecule, nucleic acid, lipid, peptide, polypeptide including an antibody such as a chimeric, humanized or fully human antibody or an antibody fragment, peptide- or non-peptide mimetic derived therefrom as well as a bispecific or 20 multispecific antibody, a single chain (e.g. scFv) or single domain antibody or an antibody-mimetic such as an anticalin or fibronectin-based binding molecule (e.g. trinectin or adnectin), etc., in isolated form or in mixture or combinations. The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described 25 above. The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above. As mentioned above, it is envisaged that the various moieties of the invention (i.e. the 30 polypeptides of the first aspect of the invention, a nucleic acid molecule of the second WO 2006/051333 PCT/GB2005/004390 59 or third aspect of the invention, a vector of the fourth aspect of the invention, a host cell of the fifth aspect of the invention, a ligand of the sixth aspect of the invention, a compound of the seventh aspect of the invention) may be useful in the therapy or diagnosis of diseases. To assess the utility of the moieties of the invention for treating 5 or diagnosing a disease one or more of the following assays may be carried out. Note that although some of the following assays refer to the test compound as being a protein/polypeptide, a person skilled in the art will readily be able to adapt the following assays so that the other moieties of the invention may also be used as the "test compound". 10 The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below. 15 According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of' impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight. 20 The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or to exhibit a detectable therapeutic or preventative effect. For 25 any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. 30 The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, WO 2006/051333 PCT/GB2005/004390 60 and tolerance/response to therapy. This amount can be determined by routine experimentation and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in 5 combination with other agents, drugs or hormones. A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the 10 individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles. Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts 15 such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991). Pharmaceutically acceptable carriers in therapeutic compositions may additionally 20 contain liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient. 25 Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated. The pharmaceutical compositions utilised in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, 30 intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see W098/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means.
WO 2006/051333 PCT/GB2005/004390 61 Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be 5 prepared. Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule. 10 If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, 15 receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously. In another approach, soluble forms of the polypeptide that retain binding affinity for 20 the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions. In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic 25 acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide. Similarly, inhibition can be achieved using 30 "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic WO 2006/051333 PCT/GB2005/004390 62 advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from 5 binding to ribosomes. Such oligonucleotides may be administered or may be generated in situ from expression in vivo. In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. 10 Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for 15 example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and may contain modified bases. RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' 20 0-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised 25 by endogenous endonucleases. For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to 30 alleviate the abnormal condition. Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide.
WO 2006/051333 PCT/GB2005/004390 63 Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate production of the polypeptide by replacing a defective gene with a corrected therapeutic gene. 5 Gene therapy of the present invention can occur in vivo or ex vivo. Ex vivo gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, in vivo gene therapy does not require isolation and purification of a patient's cells. 10 The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. Top. Microbiol. Imunol., 158, 97-129 (1992) and U.S. 15 Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the packaging cell now produces infectious viral particles 20 containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd). 25 Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue. In situations in which the polypeptides or nucleic acid molecules of the invention are disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent. 30 Vaccines according to the invention may either be prophylactic (ie. to prevent infection) or therapeutic (ie. to treat disease after infection). Such vaccines comprise immunising antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, WO 2006/051333 PCT/GB2005/004390 64 usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or 5 immunogen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, and other pathogens. Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for 10 parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The vaccine formulations of the invention may be presented in unit-dose or multi 15 dose containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation. Genetic delivery of antibodies that bind to polypeptides according to the invention 20 may also be effected, for example, as described in International patent application W098/55607. The technology referred to as jet injection (see, for example, www.powderject.com) may also be useful in the formulation of vaccine compositions. A number of suitable methods for vaccination and vaccine delivery systems are 25 described in International patent application WOOO/29428. This invention also relates to the use of nucleic acid molecules according to the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a 30 disease, or susceptibility to a disease, which results from under-expression, over expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.
WO 2006/051333 PCT/GB2005/004390 65 Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other 5 amplification techniques (see Saiki et al., Nature, 324, 163-166 (1986); Bej, et al., Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkenmeyer et al., J. Virol. Meth., 35, 117-126 (1991); Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior to analysis. In one embodiment, this aspect of the invention provides a method of diagnosing a 10 disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The method may comprise the steps of: a) contacting a sample of tissue from the patient with a nucleic acid probe under 15 stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe; b) contacting a control sample with said probe under the same conditions used in step a); c) and detecting the presence of hybrid complexes in said samples; 20 wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease. A further aspect of the invention comprises a diagnostic method comprising the steps of: a) obtaining a tissue sample from a patient being tested for disease; 25 b) isolating a nucleic acid molecule according to the invention from said tissue sample; and c) diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease. To aid the detection of nucleic acid molecules in the- above-described methods, an 30 amplification step, for example using PCR, may be included.
WO 2006/051333 PCT/GB2005/004390 66 Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be 5 distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting temperatures. The presence or absence of the mutation in the patient may be detected by contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid 10 probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand. Such diagnostics are particularly useful for prenatal and even neonatal testing. 15 Point mutations and other sequence differences between the reference gene and "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or single-strand conformational polymorphism, (see Orita et al., Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a 20 modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as 25 polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct 30 DNA sequencing (for example, Myers et al., Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and Sl protection or the chemical cleavage method (see Cotton et al., Proc. Natl. Acad. Sci. USA (1985) 85: 4397-4401).
WO 2006/051333 PCT/GB2005/004390 67 In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by in situ analysis (see, for example, Keller et al., DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be 5 analysed for mutations without need for their isolation and/or immobilisation onto a membrane. Fluorescence in situ hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck et al., Science, 250, 559-562 (1990), and Trask et al., Trends, Genet., 7, 149-154 (1991)). 10 In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, 15 genetic linkage, and genetic variability (see for example: M.Chee et al., Science (1996), Vol 274, pp 610-613). In one embodiment, the array is prepared and used according to the methods described in PCT application W095/11995 (Chee et al); Lockhart, D. J. et al. (1996) Nat. Biotech. 14: 1675-1680); and Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93: 20 10614-10619). Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a 25 chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/25116 (Baldeschweiler et al). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, 30 may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use WO 2006/051333 PCT/GB2005/004390 68 of commercially-available instrumentation. In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased 5 expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a polypeptide of the present 10 invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above with a biological sample under conditions suitable for the 15 formation of a ligand-polypeptide complex; and (b) detecting said complex. Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, 20 preferably humans, with antibody to the polypeptide under conditions suitable for complex formation The amount of standard complex formation may be quantified by various methods, such as by photometric means. Antibodies which specifically bind to a polypeptide of the invention may be used for the diagnosis of conditions or diseases characterised by expression of the polypeptide, 25 or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect the polypeptide in human body fluids or extracts of cells 30 or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several WO 2006/051333 PCT/GB2005/004390 69 of which are described above. Quantities of polypeptide expressed in subject, control and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic 5 assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient. 10 A diagnostic kit of the present invention may comprise: (a) a nucleic acid molecule of the present invention; (b) a polypeptide of the present invention; or (c) a ligand of the present invention. In one aspect of the invention, a diagnostic kit may comprise a first container 15 containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA. 20 In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention. To detect polypeptide according to the invention, a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention; and a reagent 25 useful for the detection of a binding reaction between the antibody and the polypeptide. Such kits will be of use in diagnosing a disease or susceptibility to disease, particularly diseases in which leucine-rich repeat motif containing proteins are implicated. Such diseases include, but are not limited to, diseases of the retina, retinal 30 pigment epithelium (RPE), and choroids; ocular neovascularization, ocular inflammation and retinal degenerations; diabetic retinopathy, chronic glaucoma, WO 2006/051333 PCT/GB2005/004390 70 retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization; rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy 5 and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, retinal artery occlusion, neovascularization due to penetration of the eye or ocular injury, neuropathies; Leber's, idiopathic, drug 10 induced, optic, and ischemic neropathies; spinal cord injuries, paraplegia, neurodegenerative disorders, disorders of the central nervous system, disorders of the peripheral nervous system, brain injuries, cerebrovascular diseases, Parkinson's disease, corticobasal degeneration, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post 15 traumatic brain injury, small-vessel cerebrovascular disease, dementias, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinsonism, frontotemporal dementias, Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld Jakob dementia, HIV dementia, schizophrenia with dementia, Korsakoffs psychosis, 20 stroke and trauma. Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to INSP168, INSP168-SV1, INSP149 and INSP 169. It will be appreciated that modification of detail may be made without departing from 25 the scope of the invention. Brief description of the Figures Figure 1: Amino acid alignment of INSP168, INSP168-SV1, INSP149 and INSP169 ORFs. The predicted transmembrane region is in bold. The predicted internal LRR region is boxed. 30 Figure 2: Nucleotide sequence with translation of the PCR product INSP168 cloned using primers INSP168-CP1 and INSP168-CP2. The predicted signal peptide is in bold. The predicted internal LRR region is boxed. The position and sense of the SUBSTITUTE SHEET (RULE 26) WO 2006/051333 PCT/GB2005/004390 71 primers are indicated by arrows. Figure 3: Nucleotide sequence with translation of the PCR product INSP168-SV1 cloned using primers [NSP168-CPl and INSP168-CP2. The predicted signal peptide is in bold. The predicted internal LRR region is boxed. The position and sense of the 5 primers are indicated by arrows. Figure 4: Genomic organisation of the PCR product INSP168-SV1. Figure 5: Amino acid alignment between INSP168, INSP168-SV1, INSP149 and INSP 169 and Retinal Specific Protein PAL (SwissProt Acc. Code PALPHUMAN). Figure 6: Schematic domain representation of 1NSP168, INSP168-SV1, INSP149, 10 INSP169, Retinal Specific Protein PAL (SwissProt Acc. Code PALPHUMAN) and nogo receptor homolog (SwissProt Acc. Code Q6X814). Figure 7: Effect of INSP168 on Stat-2 nuclear translocation in U373 in two distinct experiments. The two left hand columns illustrate the effect of addition of medium only, the two middle columns illustrate the effect of addition of the positive control 15 IFN-beta, and the two right hand columns illustrate the effect of addition of INSP168 to the medium. Figure 8: cDNA coding sequence and deduced peptide sequence of the cloned INSP169 extracellular domain. The position and orientation of primers used for cloning and sequencing are indicated by arrows. The sequence in bold corresponds to 20 the centrally located BamHI site used in the assembly of the full length clone. Figure 9: Nucleotide sequence of the cloned INSP169 extracellular domain. Figure 10: Peptide sequence of the cloned cDNA from the N terminus to the TM domain. Signal sequence is in italic; the leucine rich repeat region is in bold; the immunoglubulin C-2 domain is underlined; the fibronectin type3 domain is in bold 25 italic. SUBSTITUTE SHEET (RULE 26) WO 2006/051333 PCT/GB2005/004390 72 TABLE 1 Amino Acid Synonymous Groups More Preferred Synonymous Groups Ser Gly, Ala, Ser, Thr, Pro Thr, Ser Arg Asn, Lys, Gln, Arg, His Arg, Lys, His Leu Phe, Ile, Val, Leu, Met Ile, Val, Leu, Met Pro Gly, Ala, Ser, Thr, Pro Pro Thr Gly, Ala, Ser, Thr, Pro Thr, Ser Ala Gly, Thr, Pro, Ala, Ser Gly, Ala Val Met, Phe, Ile, Leu, Val Met, Ile, Val, Leu Gly Ala, Thr, Pro, Ser, Gly Gly, Ala Ile Phe, Ile, Val, Leu, Met Ile, Val, Leu, Met Phe Trp, Phe,Tyr Tyr, Phe Tyr Trp, Phe,Tyr Phe, Tyr Cys Ser, Thr, Cys Cys His Asn, Lys, Gln, Arg, His Arg, Lys, His Gln Glu, Asn, Asp, Gln Asn, Gln Asn Glu, Asn, Asp, Gln Asn, Gln Lys Asn, Lys, Gln, Arg, His Arg, Lys, His Asp Glu, Asn, Asp, Gln Asp, Glu Glu Glu, Asn, Asp, Gln Asp, Glu Met Phe, Ile, Val, Leu, Met Ile, Val, Leu, Met Trp Trp, Phe,Tyr Trp WO 2006/051333 PCT/GB2005/004390 73 TABLE 2 Amino Acid Synonymous Groups Ser D-Ser, Thr, D-Thr, allo-Thr, Met, D-Met, Met(O), D-Met(O), L Cys, D-Cys Arg D-Arg, Lys, D-Lys, homo-Arg, D-homo-Arg, Met, Ile, D-.Met, D Ile, Om, D-Orn Leu D-Leu, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met Pro D-Pro, L-I-thioazolidine-4-carboxylic acid, D-or L-1-oxazolidine 4-carboxylic acid Thr D-Thr, Ser, D-Ser, allo-Thr, Met,D-Met, Met(O), D-Met(O), Val, D-Val Ala D-Ala, Gly, Aib, B-Ala, Acp, L-Cys, D-Cys Val D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met, AdaA, AdaG Gly Ala, D-Ala, Pro, D-Pro, Aib, .beta. -Ala, Acp Ile D-Ile, Val, D-Val, AdaA, AdaG, Leu, D-Leu, Met, D-Met Phe D-Phe, Tyr, D-Thr, L-Dopa, His, D-His, Trp, D-Trp, Trans-3,4, or 5-phenylproline, AdaA, AdaG, cis-3,4, or 5-phenylproline, Bpa, D-Bpa Tyr D-Tyr, Phe, D-Phe, L-Dopa, His, D-His Cys D-Cys, S--Me--Cys, Met, D-Met, Tbr, D-Thr Gin D-Gln, Asn, D-Asn, Glu, D-Glu, Asp, D-Asp Asn D-Asn, Asp, D-Asp, Glu, D-Glu, Gln, D-Gln Lys D-Lys, Arg, D-Arg, homo-Arg, D-homo-Arg, Met, D-Met, Ile, D Ile, Om, D-Orn Asp D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln Glu D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln Met D-Met, S--Me--Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val WO 2006/051333 PCT/GB2005/004390 74 Examples Example 1: Cloning of INSP 168 and INSP168-SV1 Preparation of human cDNA templates First strand cDNA was prepared from a variety of normal human tissue total RNA 5 samples (Clontech, Stratagene, Ambion, Biochain Institute and in-house preparations) using Superscript II RNase H- Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol. Oligo (dT)15 primer (1pl at 500 pig/ml) (Promega), 2 jpg human total RNA, 1 pl 10 mM dNTP mix (10 mM each of dATP, dGTP, dCTP and dTTP at neutral pH) and sterile distilled water to a final volume of 12 ptl were 10 combined in a 1.5 ml Eppendorf tube, heated to 65 'C for 5 min and then chilled on ice. The contents were collected by brief centrifugation and 4 ptl of 5X First-Strand Buffer, 2 pl 0.1 M DTT, and 1 ptl RnaseOUT Recombinant Ribonuclease Inhibitor (40 units/pl, Invitrogen) were added. The contents of the tube were mixed gently and incubated at 42 'C for 2 min; then 1 pl (200 units) of SuperScript II enzyme was 15 added and mixed gently by pipetting. The mixture was incubated at 42 'C for 50 min and then inactivated by heating at 70 'C for 15 min. To remove RNA complementary to the cDNA, 1 pl (2 units) of E. coli RNase H (Invitrogen) was added and the reaction mixture incubated at 37 'C for 20 min. The final 21 pl reaction mix was diluted by adding 179 pl sterile water to give a total volume of 200 pl. The cDNA templates 20 used for the amplification of INSP 168 were derived from brain and eye RNA. cDNA libraries Human cDNA libraries (in bacteriophage lambda (k) vectors) were purchased from Stratagene or Clontech or prepared at the Serono Pharmaceutical Research Institute in k ZAP or k GT1O vectors according to the manufacturer's protocol (Stratagene). 25 Bacteriophage k DNA was prepared from small scale cultures of infected K coli host strain using the Wizard Lambda Preps DNA purification system according to the manufacturer's instructions (Promega, Corporation, Madison WI.). cDNA library templates used for the amplification of INSP168 were derived from brain, fetal brain, retina, and a mixed brain-lung-testis library. 30 Gene specific cloning primers for PCR A pair of PCR primers having a length of between 18 and 25 bases was designed for amplifying the predicted coding sequence of the virtual cDNA using Primer Designer WO 2006/051333 PCT/GB2005/004390 75 Software (Scientific & Educational Software, PO Box 72045, Durham, NC 27722 2045, USA). PCR primers were optimized to have a Tm close to 55 + 10 'C and a GC content of 40-60%. Primers were selected which had high selectivity for the target sequence (INSP 168) with little or no none specific priming. 5 PCR amplification of INSP]68from human cDNA templates Gene-specific cloning primers (INSP168-CP1 and INSP168-CP2, Figure 2, Figure 3 and Table 3) were designed to amplify a cDNA fragment of 614 bp covering the entire of the predicted INSP 168 cds. The primer pair was used with the human cDNA samples and cDNA libraries listed above as PCR templates. PCR was performed in a 10 final volume of 50 tl containing IX Platinum@ Taq High Fidelity (HiFi) buffer, 2 mM MgSO4, 200 pLM dNTPs, 0.2 pM of each cloning primer, 1 unit of Platinum@ Taq DNA Polymerase High Fidelity (HiFi) (Invitrogen), and approximately 20 ng of template cDNA. Cycling was performed using an MJ Research DNA Engine, programmed as follows: 94 'C, 2 min; 40 cycles of 94 'C, 30 sec, 55 'C, 30 sec, and 15 68 'C, 1 min; followed by 1 cycle at 68 'C for 7 min and a holding cycle at 4 'C. 30 pl of each amplification product was visualized on a 0.8 % agarose gel in 1 X TAE buffer (Invitrogen). Products of approximately the expected molecular weight were seen in the PCR products amplified from brain and eye cDNA templates. These products was purified from the gel using the Promega Wizard@ PCR Preps DNA 20 Purification System, eluted in 50 pl of water and subcloned directly. Subcloning of PCR Products The PCR products were subcloned into the topoisomerase I modified cloning vector (pCR4-TOPO) using the TA cloning kit purchased from the Invitrogen Corporation using the conditions specified by the manufacturer. Briefly, 4 pl of gel purified PCR 25 product was incubated for 15 min at room temperature with 1 pl of TOPO vector and 1 pil salt solution. The reaction mixture was then transformed into E. coli strain TOP10 (Invitrogen) as follows: a 50 pl aliquot of One Shot TOP10 cells was thawed on ice and 2 pl of TOPO reaction was added. The mixture was incubated for 15 min on ice and then heat shocked by incubation at 42 'C for exactly 30 s. Samples were 30 returned to ice and 250 pl of warm (room temperature) SOC media was added. Samples were incubated with shaking (220 rpm) for 1 h at 37 'C. The transformation mixture was then plated on L-broth (LB) plates containing ampicillin (100 ptg/ml) and WO 2006/051333 PCT/GB2005/004390 76 incubated overnight at 37 'C. Colony PCR Colonies were inoculated into 50 pl sterile water using a sterile toothpick. A 10 p1 aliquot of the inoculum was then subjected to PCR in a total reaction volume of 20 pl 5 containing 1X AmpliTaqTM buffer, 200 pM dNTPs, 20 pmoles of T7 primer, 20 poles of T3 primer, 1 unit of AmpliTaqTM (Applied Biosystems) using an MJ Research DNA Engine. The cycling conditions were as follows: 94 'C, 2 min; 30 cycles of 94 'C, 30 sec, 48 'C, 30 sec and 72 'C for 1 min. Samples were maintained at 4 'C (holding cycle) before further analysis. 10 PCR reaction products were analyzed on 1 % agarose gels in 1 X TAE buffer. Colonies which gave PCR products of approximately the expected molecular weight (614 bp or 267 bp + 105 bp due to the multiple cloning site (MCS)) were grown up overnight at 37 'C in 5 ml L-Broth (LB) containing ampicillin (100 pg /ml), with shaking at 220 rpm. 15 Plasmid DNA preparation and sequencing Miniprep plasmid DNA was prepared from the 5 ml culture using a Biorobot 8000 robotic system (Qiagen) or Wizard Plus SV Minipreps kit (Promega cat. no. 1460) according to the manufacturer's instructions. Plasmid DNA was eluted in 80 p1 of sterile water. The DNA concentration was measured using a Spectramax 190 20 photometer (Molecular Devices). Plasmid DNA (200-500 ng) was subjected to DNA sequencing with the T7 and T3 primers using the BigDye Terminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. The primer sequences are shown in Table 3. Sequencing reactions were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. 25 LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer. Sequence analysis identified a clone, amplified from brain cDNA, which matched the expected INSP168 sequence. The plasmid map of the cloned PCR product is pCR4 TOPO-INSP168. The nucleotide sequence with translation of the PCR product INSP168 is shown in Figure 2. ~30 A second clone was identified, also amplified from brain, which contained the INSP168 cds with a 77 bp insertion towards the 3' end of the sequence. This led to an insertion of 32 amino acids and a frameshift such that an ORF of 229 amino acids was WO 2006/051333 PCT/GB2005/004390 77 produced. The insertion represented an additional exon, giving an ORF encoded in 4 exons. A stop codon was not identified but one present 2 bp downstream of the 3' end of the new sequence in genomic DNA was assumed to be functional. The nucleotide sequence with translation of the PCR product INSP168-SV1 is shown in Figure 3. 5 This clone was named pCR4-TOPO-INSPl68-SVl. The genomic organisation of the INSP168-SV1 cds is shown in Figure 4. The plasmid map of the cloned PCR product is pCR4-TOPO-INSP168-SV1. The position of the INSP168-CP1 amplification primer meant that the final base of the cds was missing - this base was added during transfer into the Gateway entry vector pDONR 221 (see below). 10 Table 3: INSP168 cloning and sequencing primers Primer Sequence (5'-3') INSP168-CP1 GAG CAA TGC ATC TCT TTG CAT GTC INSP168-CP2 AGC CGT AAC GTT CTA TCA GC INSP168-EX1 GCA GGC TTC GCC ACC ATG CAT CTC TTT GCA TGT CT INSP168-EX2 TG ATG GTG ATG GTG GCC AAG AAT AAT CCT GCT TGG GCP Forward G GGG ACA AGT TTG TAC AAA AAA GCA GGC TTC GCC ACC GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TCA ATG GTG ATG GCP Reverse GTG ATG GTG pEAK12F GCC AGC TTG GCA CTT GAT GT pEAK12R GAT GGA GGT GGA CGT GTC AG 21M13 TGT AAA ACG ACG GCC AGT M13REV CAG GAA ACA GCT ATG ACC T7 TAA TAC GAC TCA CTA TAG G T3 ATT AAC CCT CAC TAA AGG Underlined sequence = Kozak sequence Bold = Stop codon Italic sequence = His tag WO 2006/051333 PCT/GB2005/004390 78 Example 2: Construction of Mammalian Cell Expression Vectors for INSP 168 pCR4-TOPO-1NSP168 was used as PCR template to generate pEAK12d and pDEST12.2 expression clones containing the INSP168 ORF sequence with a 3' sequence encoding a 6HIS tag using the Gateway T m cloning methodology (Invitrogen). 5 Generation of Gateway compatible NSP168 ORF fused to an in f-ame 6HIS tag sequence The first stage of the Gateway cloning process involves a two step PCR reaction which generates the ORF of INSP168 flanked at the 5' end by an attBl recombination site and Kozak sequence, and flanked at the 3' end by a sequence encoding an in frame 6 10 histidine (6HIS) tag, a stop codon and the attB2 recombination site (Gateway compatible cDNA). The first PCR reaction (in a final volume of 50 pl) contains respectively: 1 p1 (40 ng) of plasmid pCR4-TOPO-INSPl68, 1.5 pl dNTPs (10 mM), 10 pl of loX Pfx polymerase buffer, 1 pl MgSO4 (50 mM), 0.5 pl each of gene specific primer (100 pM) (INSP168-EX1 and TNSP168-EX2), and 0.5 pl Platinum Pfx DNA polymerase 15 (Invitrogen). The PCR reaction was performed using an initial denaturing step of 95 'C for 2 min, followed by 12 cycles of 94 'C for 15 s; 55 'C for 30 s and 68 'C for 2 min; and a holding cycle of 4 'C. The amplification product was directly purified using the Wizard PCR Preps DNA Purification System (Promega) and recovered in 50 d sterile water according to the manufacturer's instructions. 20 The second PCR reaction (in a final volume of 50 pl) contained 10 pl purified PCR 1 product, 1.5 pl dNTPs (10 mM), 5 pl of lOX Pfx polymerase buffer, 1 pl MgSO4 (50 mM), 0.5 pl of each Gateway conversion primer (100 ptM) (GCP forward and GCP reverse) and 0.5 pl of Platinum Pfx DNA polymerase. The conditions for the 2nd PCR reaction were: 95 'C for 1 min; 4 cycles of 94 'C, 15 sec; 50 'C, 30 sec and 68 'C for 2 25 min; 25 cycles of 94 'C, 15 sec; 55 C , 30 sec and 68 'C, 2 min; followed by a holding cycle of 4 'C. PCR product was visualized on 0.8 % agarose gel in 1 X TAE buffer (Invitrogen) and the band migrating at the predicted molecular mass (661 bp) was purified from the gel using the Wizard PCR Preps DNA Purification System (Promega) and recovered in 50 pl sterile water according to the manufacturer's instructions.
WO 2006/051333 PCT/GB2005/004390 79 Subcloning of Gateway compatible INSP168 ORF into Gateway entry vector pDONR221 and expression vectors pEAK12d and pDEST12.2 The second stage of the Gateway cloning process involves subcloning of the Gateway 5 modified PCR products into the Gateway entry vector pDONR221 (Invitrogen) as follows: 5 pl of purified product from PCR2 were incubated with 1.5 pl pDONR221 vector (0.1 ptg/pl), 2 pl BP buffer and 1.5 tl of BP clonase enzyme mix (Invitrogen) in a final volume of 10 pl at RT for 1 h. The reaction was stopped by addition of proteinase K 1 pl (2 ptg/pl) and incubated at 37 'C for a further 10 min. An aliquot of this reaction 10 (1 pl) was used to transform E. coli DH1OB cells by electroporation as follows: a 25 pl aliquot of DH1OB electrocompetent cells (Invitrogen) was thawed on ice and 1 pl of the BP reaction mix was added. The mixture was transferred to a chilled 0.1 cm electroporation cuvette and the cells electroporated using a BioRad Gene-PulserTM according to the manufacturer's recommended protocol. SOC media (0.5 ml) which had 15 been pre-wanned to room temperature was added immediately after electroporation. The mixture was transferred to a 15 ml snap-cap tube and incubated, with shaking (220 rpm) for 1 h at 37 'C. Aliquots of the transformation mixture (10 pl and 50 pl) were then plated on L-broth (LB) plates containing kanamycin (40 ptg/ml) and incubated overnight at 37 0 C. 20 Plasmid mini-prep DNA was prepared from 5 ml cultures from 6 of the resultant colonies using a Qiaprep BioRobot 8000 system (Qiagen). Plasmid DNA (150-200 ng) was subjected to DNA sequencing with 21M13 and M13Rev primers using the BigDyeTerminator system (Applied Biosystems cat. no. 4336919) according to the manufacturer's instructions. The primer sequences are shown in Table 3. Sequencing 25 reactions were purified using Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) then analyzed on an Applied Biosystems 3700 sequencer. Plasmid eluate (2 pl or approx. 150 ng) from one of the clones which contained the correct sequence (pENTRINSP168-6HIS) was then used in a recombination reaction containing 1.5 pl of either pEAK12d vector or pDEST12.2 vector (0.1 ptg / pl), 2 pl LR 30 buffer and 1.5 pl of LR clonase (Invitrogen) in a final volume of 10 pl. The mixture was incubated at RT for 1 h, stopped by addition of proteinase K (2 pg) and incubated at 37 'C for a further 10 min. An aliquot of this reaction (1 ul) was used to transform E. coli DH1 OB cells by electroporation as follows: a 25 pl aliquot of DH1 OB electrocompetent cells (Invitrogen) was thawed on ice and 1 pl of the LR reaction mix was added. The WO 2006/051333 PCT/GB2005/004390 80 mixture was transferred to a chilled 0.1 cm electroporation cuvette and the cells electroporated using a BioRad Gene-PulserTM according to the manufacturer's recommended protocol. SOC media (0.5 ml) which had been pre-warmed to room temperature was added immediately after electroporation. The mixture was transferred to 5 a 15 ml snap-cap tube and incubated, with shaking (220 rpm) for 1 h at 37 'C. Aliquots of the transformation mixture (10 d and 50 pl) were then plated on L-broth (LB) plates containing ampicillin (100 pLg/ml) and incubated overnight at 37 'C. Plasmid mini-prep DNA was prepared from 5 ml cultures from 6 of the resultant colonies subcloned in each vector using a Qiaprep Bio Robot 8000 (Qiagen). Plasmid 10 DNA (200-500 ng) in the pEAK12d vector was subjected to DNA sequencing with pEAK12F and pEAK12R primers as described above. Plasmid DNA (200-500 ng) in the pDEST12.2 vector was subjected to DNA sequencing with 21M13 and M13Rev primers as described above. Primer sequences are shown in Table 3. CsCl gradient purified maxi-prep DNA was prepared from a 500 ml culture of the 15 sequence verified clone (pEAK12dINSP168-6HIS) using the method described by Sambrook J. et al., 1989 (in Molecular Cloning, a Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press). Plasmid DNA was resuspended at a concentration of 1 pig/pil in sterile water (or 10 mM Tris-HCl pH 8.5) and stored at -20 'C. Endotoxin-free maxi-prep DNA was prepared from a 500 ml culture of the sequence 20 verified clone (pDEST12.2_INSP168-6HIS) using the EndoFree Plasmid Mega kit (Qiagen) according to the manufacturer's instructions. Purified plasmid DNA was resuspended in endotoxin free TE buffer at a final concentration of at least 3 pig/pl and stored at -20 *C. Example 3: Tissue Distribution and Expression Levels of INSP168 25 Further experiments may now be performed to determine the tissue distribution and expression levels of the INSP168 polypeptide in vivo, on the basis of the nucleotide and amino acid sequence disclosed herein. The presence of the transcripts for 1NSP168 may be investigated by PCR of cDNA from different human tissues. The INSP168 transcripts may be present at very low 30 levels in the samples tested. Therefore, extreme care is needed in the design of experiments to establish the presence of a transcript in various human tissues as a small amount of genomic contamination in the RNA preparation will provide a false WO 2006/051333 PCT/GB2005/004390 81 positive result. Thus, all RNA should be treated with DNAse prior to use for reverse transcription. In addition, for each tissue a control reaction may be set up in which reverse transcription was not undertaken (a -ve RT control). For example, 1 pg of total RNA from each tissue may be used to generate cDNA using 5 Multiscript reverse transcriptase (ABI) and random hexamer primers. For each tissue, a control reaction is set up in which all the constituents are added except the reverse transcriptase (-ve RT control). PCR reactions are set up for each tissue on the reverse transcribed RNA samples and the minus RT controls. INSP168-specific primers may readily be designed on the basis of the sequence information provided herein. The 10 presence of a product of the correct molecular weight in the reverse transcribed sample together with the absence of a product in the minus RT control may be taken as evidence for the presence of a transcript in that tissue. Any suitable cDNA libraries may be used to screen for the INSP168 transcripts, not only those generated as described above. 15 The tissue distribution pattern of the INSP 168 polypeptides will provide further useful information in relation to the function of those polypeptides. Example 4: Expression and Purification of INSP168 Further experiments may now be performed using expression vectors. Transfection of mammalian cell lines with these vectors may enable the high level expression of the 20 INSP168 polypeptides and thus enable the continued investigation of the functional characteristics of the INSP168 polypeptides. The following material and methods are an example of those suitable in such experiments. Cell Culture Human Embryonic Kidney 293 cells expressing the Epstein-Barr virus Nuclear 25 Antigen (HEK293-EBNA, Invitrogen) are maintained in suspension in Ex-cell VPRO serum-free medium (seed stock, maintenance medium, JRH). Sixteen to 20 hours prior to transfection (Day-1), cells are seeded in 2x T225 flasks (50ml per flask in DMEM / F12 (1:1) containing 2% FBS seeding medium (JRH) at a density of 2x10 5 cells/ml). The next day (transfection day 0) transfection takes place using the 30 JetPEITM reagent (2pl/ptg of plasmid DNA, PolyPlus-transfection). For each flask, plasmid DNA is co-transfected with GFP (fluorescent reporter gene) DNA. The transfection mix is then added to the 2xT225 flasks and incubated at 37C (5%CO 2
)
WO 2006/051333 PCT/GB2005/004390 82 for 6 days. Confirmation of positive transfection may be carried out by qualitative fluorescence examination at day 1 and day 6 (Axiovert 10 Zeiss). On day 6 (harvest day), supernatants from the two flasks are pooled and centrifuged (e.g. 4'C, 400g) and placed into a pot bearing a unique identifier. One aliquot (500l) 5 is kept for QC of the 6His-tagged protein (internal bioprocessing QC). Scale-up batches may be produced by following the protocol called "PEI transfection of suspension cells", referenced BP/PEI/HH/02/04, with PolyEthylenelmine from Polysciences as transfection agent. Purification process 10 The culture medium sample containing the recombinant protein with a C-terminal 6His tag is diluted with cold buffer A (50mM NaH 2
PO
4 ; 600mM NaCl; 8.7 % (w/v) glycerol, pH 7.5). The sample is filtered then through a sterile filter (Millipore) and kept at 4'C in a sterile square media bottle (Nalgene). The purification is performed at 4'C on the VISION workstation (Applied 15 Biosystems) connected to an automatic sample loader (Labomatic). The purification procedure is composed of two sequential steps, metal affinity chromatography on a Poros 20 MC (Applied Biosystems) column charged with Ni ions (4.6 x 50 mm, 0.83ml), followed by gel filtration on a Sephadex G-25 medium (Amersham Pharmacia) column (1,0 x 10cm). 20 For the first chromatography step the metal affinity column is regenerated with 30 column volumes of EDTA solution (100mM EDTA; 1M NaCl; pH 8.0), recharged with Ni ions through washing with 15 column volumes of a 100mM NiSO 4 solution, washed with 10 column volumes of buffer A, followed by 7 column volumes of buffer B (50mM NaH 2
PO
4 ; 600mM NaCl; 8.7 % (w/v) glycerol, 400mM; imidazole, 25 pH 7.5), and finally equilibrated with 15 column volumes of buffer A containing 15mM imidazole. The sample is transferred, by the Labomatic sample loader, into a 200ml sample loop and subsequently charged onto the Ni metal affinity column at a flow rate of 1 Oml/min. The column is washed with 12 column volumes of buffer A, followed by 28 column volumes of buffer A containing 20mM imidazole. During the 30 20mM imidazole wash loosely attached contaminating proteins are eluted from the column. The recombinant His-tagged protein is finally eluted with 10 column volumes of buffer B at a flow rate of 2ml/min, and the eluted protein is collected.
WO 2006/051333 PCT/GB2005/004390 83 For the second chromatography step, the Sephadex G-25 gel-filtration column is regenerated with 2ml of buffer D (L.137M NaCl; 2.7mM KCl; 1.5mM KH 2
PO
4 ; 8mM Na 2
HPO
4 ; pH 7.2), and subsequently equilibrated with 4 column volumes of buffer C (137mM NaCl; 2.7mM KCl; 1.5mM KH 2
PO
4 ; 8mM Na 2
HPO
4 ; 20% (w/v) glycerol; 5 pH 7.4). The peak fraction eluted from the Ni-column is automatically loaded onto the Sephadex G-25 column through the integrated sample loader on the VISION and the protein is eluted with buffer C at a flow rate of 2 ml/min. The fraction was filtered through a sterile centrifugation filter (Millipore), frozen and stored at -80'C. An aliquot of the sample is analyzed on SDS-PAGE (4-12% NuPAGE gel; Novex) 10 Western blot with anti-His antibodies. The NuPAGE gel may be stained in a 0.1 % Coomassie blue R250 staining solution (30% methanol, 10% acetic acid) at room temperature for lh and subsequently destained in 20% methanol, 7.5% acetic acid until the background is clear and the protein bands clearly visible. Following the electrophoresis the proteins are electrotransferred from the gel to a 15 nitrocellulose membrane. The membrane is blocked with 5% milk powder in buffer E (137mM NaCl; 2.7mM KCl; 1.5mM KH 2
PO
4 ; 8mM Na 2
HPO
4 ; 0.1 % Tween 20, pH 7.4) for 1h at room temperature, and subsequently incubated with a mixture of 2 rabbit polyclonal anti-His antibodies (G-18 and H-15, 0.2pg/nl each; Santa Cruz) in 2.5% milk powder in buffer E overnight at 4*C. After a further 1 hour incubation at 20 room temperature, the membrane is washed with buffer E (3 x 10min), and then incubated with a secondary HRP-conjugated anti-rabbit antibody (DAKO, HRP 0399) diluted 1/3000 in buffer E containing 2.5% milk powder for 2 hours at room temperature. After washing with buffer E (3 x 10 minutes), the membrane is developed with the ECL kit (Amersham Pharmacia) for 1 min. The membrane is 25 subsequently exposed to a Hyperfilm (Amersham Pharmacia), the film developed and the western blot image visually analysed. For samples that showed detectable protein bands by Coomassie staining, the protein concentration may be determined using the BCA protein assay kit (Pierce) with bovine serum albumin as standard. 30 Furthermore, overexpression or knock-down of the expression of the polypeptides in cell lines- may be used to determine the effect on transcriptional activation of the host cell genome. Dimerisation partners, co-activators and co-repressors of the INSP168 WO 2006/051333 PCT/GB2005/004390 84 polypeptides may be identified by immunoprecipitation combined with Western blotting and immunoprecipitation combined with mass spectroscopy. Example 5: Biological Significance of INSP168, INSP168-SV1, INSP149 and INSP169 5 As explained above, INSP168, INSP168-SV1, INSP149 and INSP169 are structurally related to the Retinal Specific Protein PAL (SwissProt Acc. Code PALPHUMAN) and to a nogo receptor homolog (SwissProt Acc. Code Q6X814). An amino acid alignment between INSP168, INSP168-SV1, INSP149 and INSP169 and PAL is shown in Figure 5, and the schematic representation of domains is shown in Figure 6. 10 PAL may be implicated in diseases of the retina, retinal pigment epithelium (RPE), and choroids (see for example JP2001128686). These include ocular neovascularization, ocular inflammation and retinal degenerations. Specific examples of these disease states include diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal 15 neovascularization, subretinal neovascularization; rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, 20 cystoid macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, and retinal artery occlusion, and, neovascularization due to penetration of the eye or ocular injury. Additional relevant disease include the neuropathies, such as Leber's, idiopathic, drug-induced, optic, and ischemic neropathies. 25 Nogo receptor-like proteins could be major inhibitors of CNS neuronal regeneration (Schwab ME. Curr Opin Neurobiol. 2004 Feb;14(1):118-24; Teng et al. J Neurochem. 2004 May;89(4):801-6). Animals treated with antibodies targeted to Nogo-A always showed a higher degree of recovery in various behavioural tests (e.g. IN-1 Fab' fragments or new purified IgGs against Nogo-A). In addition, a Nogo-66 antagonistic 30 peptide (NEP1-40) effected significantly axon growth of the corticospinal tract and improved functional recovery in rats inflicted with mid-thoracic spinal cord hemisections. Subcutaneous administration of NEP1-40 in spinal cord lesioned WO 2006/051333 PCT/GB2005/004390 85 animals resulted in extensive growth of corticospinal axons, sprouting of serotonergic fibres, synapse formation and enhanced locomotor recovery. Soluble Fe fusion proteins of the Nogo receptor subunit NgR, which blocks Nogo, significantly reduce the inhibitory activity of myelin. Similar results were obtained after Nogo gene 5 deletions and blockade of the downstream messengers Rho-A and ROCK in animal models. The leucine-rich repeat domain of SLIT proteins is sufficient for guiding both axon projection and neuronal migration in vitro (the LRR region of SLIT is structurally related to the LRR region of INSP168, INSP168-SV1, INSP149 and INSP169). SLIT 10 like proteins are thought to act as molecular guidance cue in cellular migration, and function appears to be mediated by interaction with roundabaout homolog receptors (bind ROBO1 and ROBO2 with high affinity). During neural development, SLIT are involved in axonal navigation at the ventral midline of the neural tube and projection of axons to different regions. In spinal chord development, SLIT may play a role in 15 guiding commissural axons once they reached the floor plate by modulating the response to netrin. SLIT may be implicated in spinal chord midline post-crossing axon repulsion. In the developing visual system appears to function as repellent for retinal ganglion axons by providing a repulsion that directs these axons along their appropriate paths prior to, and after passage through, the optic chiasm. In vitro, SLIT 20 collapses and repels retinal ganglion cell growth cones. SLIT seems to play a role in branching and arborization of CNS sensory axons, and in neuronal cell migration. In vitro, Slit homolog 2 protein N-product, but not Slit homolog 2 protein C-product, repells olfactory bulb (OB) but not dorsal root ganglia (DRG) axons, induces OB growth cones collapse and induces branching of DRG axons. SLIT seems to be 25 involved in regulating leukocyte migration. INSP168, INSP168-SVl, INSP149 and INSP169 and/or fragments thereof (e.g. fragments containing the LRR region) can be useful in the diagnosis and/or treatment of diseases for which other (e.g. above mentioned PAL- and Nogo receptor-like proteins) structurally related proteins demonstrate therapeutic activity. 30 As such, INSP168, INSP168-SV1, INSP149 and INSP169 may be implicated in diseases of the retina, spinal cord injuries (e.g. paraplegia) and neurodegenerative disorders. These include disorders of the central nervous system as well as disorders of the peripheral nervous system. Neurodegenerative disorders include, but are not WO 2006/051333 PCT/GB2005/004390 86 limited to, brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease (including amyotrophic lateral sclerosis, ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post- traumatic brain injury, and small-vessel cerebrovascular disease. Dementias, 5 such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism, frontotemporal dementias (including Pick's disease), progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoffs psychosis, as well as stroke and trauma. 10 Thus, INSP149, INSP168, INSP168-SV1 and ITNSP169 may be implicated in diseases of the retina, retinal pigment epithelium (RPE), and choroids; ocular neovascularization, ocular inflammation and retinal degenerations; diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal neovascularization; 15 rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, retinitis pigmentosa, retinal 20 vein occlusion, proliferative vitreoretinopathy, angioid streak, retinal artery occlusion, neovascularization due to penetration of the eye or ocular injury, neuropathies; Leber's, idiopathic, drug-induced, optic, and ischemic neropathies; spinal cord injuries, paraplegia, neurodegenerative disorders, disorders of the central nervous system, disorders of the peripheral nervous system, brain injuries, cerebrovascular 25 diseases, Parkinson's disease, corticobasal degeneration, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post- traumatic brain injury, small-vessel cerebrovascular disease, dementias, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinsonism, frontotemporal dementias, Pick's disease, 30 progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, Korsakoffs psychosis, stroke and trauma.
WO 2006/051333 PCT/GB2005/004390 87 Example 6: Neuroprotective activities of INSP168 Neuro-inflammation is a common feature of several neurological diseases, traumatic situations (at central or peripheral level), stroke (brain, heart, renal), or infectious diseases (mediated by viral agents such as HIV or bacterial agents such as 5 meningitis), leading to an excessive inflammatory response in central nervous system. Many stimuli, originated by neuronal or oligodendroglial cells suffering due to these various conditions, can trigger neuro-inflammation. In particular, astrocytes can secrete various chemokines and cytokines, inducing a recruitment of additional leukocytes that in their turn will further stimulate astrocytes, leading to an 10 exacerbated response. In chronic neurodegenerative diseases such as multiple sclerosis (MS), spinal muscular atrophies (SMA), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), or amylotrophic lateral sclerosis (ALS), the presence of persistent neuro-inflammation is thought to be involved in the progression of the disease and in the case of AD in the secondary events such as 15 micro-hemorrhagic events (Cacquevel M et al., Curr Drug Targets. 2004, 5: 529-534; Chavarria A et al., Autoimmun Rev. 2004, 3: 251-260; Ambrosini E and Aloisi F, Neurochem Res. 2004, 29: 1017-103 8). The biological properties of INSP168 related to neuroprotection, maintenance of axonal integrity, myelination and re-/generation of myelin producing cells, can be 20 tested in various assays involving cell lines. For example, the neuroimmunodulatory effects of a compound can be evaluated in U373, a human astroglioma cell line in which the nuclear translocation of specific regulatory proteins involved in cytokine/chemokine expression can be quantified (Le Roy E et al., J Virol. 1999, 73: 6582-9; Jin Y et al., J Infect Dis. 1998, 177: 1629-1638; Acevedo-Duncan M et al., 25 Cell Growth Differ. 1995, 6: 1353-1365). A series of assays was performed on the human astroglioma cell line U373 to check whether INSP168 can affect the translocation of transcription factors such as Stat-2 (Signal transducer and activator of transcription-2, a transcription factor induced by cytokines and modulating IFNbeta response; Banninger G and Reich NC, J Biol 30 Chem. 2004, 279: 39199-39206; Leonard WJ, Int J Hematol. 2001, 73: 271-277) from the cytoplasm to the nucleus.
WO 2006/051333 PCT/GB2005/004390 88 U373 cells (ECACC ref no: 89081403) were seeded at the density of 4000 cells/well in 96-well-plates (Packard ViewPlate-96, black; Cat. No. 6005225) in 80 ptl of DMEM containing 10% FCS (Fetak Calf Serum) and left overnight at 37 0 C in a humidified 5% C02 incubator. The following day, 20 pl of culture medium alone, or 5 containing the protein to test (medium added with 1000 IU/ml of recombinant IFNbeta, or medium from His-tagged INSPI68 expressing cells) was added to the cells. Thirty minutes after, the medium was removed and cells were fixed with 3.7% formaldehyde (Sigma; Cat. No. 25,254-9) and processed for immunostaining using commercial kits (for c-Jun immunostaining, Cellomics c-Jun activation HitKit, Cat. 10 No. K01-0003-1; for Stat-2, Cellomics Stat-2 activation HitKit, Cat. No. K01-0005-1) according to the manufacturer's instructions. After staining, plates were read on an image analysis system (ArrayScan II HCS System; Cellomics). Results were expressed as "nuclear translocation units". The nuclear translocation unit is the measure of the fluorescence intensity of the target in the nuclear region minus 15 that of the cytoplasm region, reported as an average for all analyzed cells in the well (approx. 100 cells/well). In order to compare several experiments, results were also expressed as the percentage of maximal stimulation calculated with the positive control (IFNbeta). Statistics were performed using Student's T test or measure analysis of variance (ANOVA) and one-way ANOVA, followed by Dunnett's test 20 depending of the number of groups per experiments. The level of significance was set at p < 0.05. The results were expressed as mean standard error of the mean (s.e.m.). The addition of a culture medium containing INSP168 was found to stimulate Stat-2 nuclear translocation in U373 cells, as indicated by the statistically significant increase of fluorescence intensity in the nuclei. The response corresponds to 20-30% 25 of the maximal level achieved with IFNbeta, the positive control (Fig. 7; ** means p<0.005, *** means p<0.0005). This first series of experiments revealed that INSP168 has the capacity to stimulate intracellular signaling by inducing Stat-2 nuclear translocation in U373 cells. Activation of Stat proteins signaling is known to be associated with 30 immunomodulation and eventually cell proliferation (Pfitzner E et al., Curr Pharm Des. 2004, 10: 2839-2850).
WO 2006/051333 PCT/GB2005/004390 89 Example 7: Cloning of the INSP169 extracellular domain (INSP169ec) INSP169 is a re-prediction of INSP149 which encodes a protein of 679 amino acids spanning 4 coding exons. A transmembrane (TM) domain is predicted near the C terminus. The N-terminal extracellular domain extends over 580 amino acids and 5 includes a cluster of 4 Leucine rich repeats (LRR) flanked by Cys-rich domains, an IgC-2 domain and a fibronectin type 3 domain. The extracellular domain of this prediction has been cloned. The cloning strategy used was to prepare an initial pool of RNAs from a wide variety of human tissues (see below) and from this to make a single preparation of multi 10 tissue polyA+ mRNA as template for reverse transcription. Gene specific cDNA primers were designed for a small set of the predictions (typically 5-10 sequences), and aliquots of the resulting cDNA mix provided templates for separate PCR reactions using primers designed to obtain the corresponding coding region. Amplified fragments were then purified by gel electorphoresis and cloned into the 15 Bluescript cloning vector by virtue of specific restriction sites added to the ends of the PCR primers. In the case of INSP169ec, a two step strategy was employed which makes use of a unique BamHI restriction site in the central part of this sequence. A first RT-PCR was performed to obtain the 1063nt sequence between the TM domain to the BamHI site; 20 a second RT-PCR was performed to obtain the remaining 683nt sequence upstream of the BamHI site as far as the initiator methionine codon. These two fragments were then assembled following BamHI digestion and ligation. The gene specific primers used are described below and in Table 4 below. A cDNA of 1740 nucleotides was obtained and sequence analysis of this insert revealed the 25 predicted cDNA sequence for the complete extracellular domain of INSP169. The coding region and position of the oligonucleotide primers used in the cloning of INSP169ec are shown in Figure 8. 7.1 Preparation of a human multi-tissue cDNA template A preparation of human RNA was prepared by mixing approximately 10 ptg total 30 RNA from each of the following sources: WO 2006/051333 PCT/GB2005/004390 90 Brain (Clontech), Heart (Clontech), Kidney (Clontech), Liver (Clontech), Lung (Clontech), Placenta (Clontech), Skeletal Muscle (Clontech), Small Intestine (Clontech), Spleen (Clontech), Thymus (Clontech), Uterus (Clontech) Bone Marrow (Clontech) Thyroid (Clontech), Ovary (Ambion), Testis (Ambion), Prostate 5 (Ambion), Skin (Resgen), Pancreas (Clontech), Salivary gland (BD Biosciences), Adrenal gland (BD Biosciences), Breast (Ambion), Pituitary gland (BioChain Institut), Stomach (Ambion), Mammary gland (Clontech), Lymph Node (BioChain Institut), Adipose tissue (BioChain Institut), Bladder (BioChain Institut), Appendix (BioChain Institut), Artery (BioChain Institut), Throat (BioChain Institut), Universal 10 Human Reference (Stratagene), Foetal Kidney (Stratagene), Foetal Brain (BioChain Institut), Foetal Spleen (BioChain Institut), Foetal Liver (BioChain Institut), Foetal Heart (BioChain Institut), Foetal Lung (BioChain Institut), Peripheral blood monocytes (prepared in-house from buffy coat). The resulting pool of total RNA was fractionated by chromatography on a pre-packed 15 oligo-dT column (Stratagene) according to the protocol supplied by the manufacturer. Approximately 400tg total RNA yielded 16pg polyA+ mRNA which was aliquotted and frozen at -80 0 C. 7.2 RT-PCR cloning ofINSP169ec 7.2.1 Stage 1: Cloning of nucleotides 678-1740 20 7.2.1.1 cDNA synthesis In the first stage of cloning, a gene specific cDNA primer for INSP169 (AS502) located in the TM domain, was pooled with gene specific cDNA primers for 9 other predictions, each at a final concentration of 1pM. The pooled cDNA primer set was diluted 10 fold into 50pl of a mixutre containing 1 x RT buffer, 500pM each dNTPs, 25 1OU/pl RNAguard (Pharmacia) and 1pg denatured polyA* RNA prepared as described above. cDNA synthesis was initiated by addition of 1OU Omniscript reverse transcriptase (Qiagen) and allowed to proceed for 1h at 37 'C. At the end of the reaction, 5pl of the cDNA mix was used for PCR amplification as described below.
WO 2006/051333 PCT/GB2005/004390 91 7.2.1.2 PCR amplification for INSP169 nucleotides 678-1740 Top strand (AS503) and bottom strand (AS504) PCR primers (see Table 4) were designed to span the predicted coding sequence between an internal BamHI site and the TM domain. EcoRI restrictions sites were added at the 5' end of each primer. A 5 reaction mixture was set up containing 1 x PCR buffer, 0.2mM each dNTP, 0.5pM each PCR primer, 5d cDNA above, and the PCR reaction was initiated by addition of 5U PfuTurbo (Stratagene). Cycling conditions for 'touchdown' PCR were: 94 'C 2 min (I cycle); 94 'C 30 sec, 64 'C (decreasing by 1 'C each cycle) 30 see, 72 'C 90 sec (14 cycles); 94 'C 30 see, 50 'C 30 see, 72 'C 90 sec (25 cycles); 72 'C 7 min (1 10 cycle). An aliquot of the PCR reaction was analysed by electrophoresis in a 0.8% agarose gel and the remainder was purified using the Wizard PCR Cleanup System (Promega) as recommended by the manufacturer, prior to subcloning of the PCR products. 7.2.1.3 Subcloning PCR products 15 An aliquot of the purified PCR reation was digested with EcoRI (New England Biolabs) for 2h at 37 'C using the enzyme buffer supplied by the manufacturer. In parallel, an appropriate amount of the Bluescript BSKI cloning vector was digested with EcoRI and dephosphorylated using calf intestinal alkaline phosphatase (Roche Diagnostics) according to the supplier's recommendations. The full length linearized 20 and dephosphorylated cloning vector was separated on a 0.8% agarose gel, excised and purified using the Wizard Cleanup System (Promega) according to the protocol provided by the manufacturer. The purified vector DNA and PCR products were mixed in a molar ratio of 1:3 and precipitated overnight at -20 'C in the presence of 2.5 volumes ethanol. The precipitated DNA was recovered by centrifugation, washed 25 in 70% ethanol, dried under vacuum and ligated in a final volume of 10pl using the Rapid Ligation Kit (Roche Diagnostics) according to the protocol supplied by the manufacturers. The ligation mixture was then used to transform E. coli strain JM 101 as follows: 50 pd aliquots of competent JM101 cells were thawed on ice and 1pl or 5pl of the ligation 30 mixture was added. The cells were incubated for 40 min on ice and then heat shocked WO 2006/051333 PCT/GB2005/004390 92 by incubation at 42 'C for 2min. iml of wann (room temperature) L-Broth (LB) was added and samples were incubated for a further 1 h at 37 'C. The transformation mixture was then plated on LB plates containing ampicillin (100 pIg/ml) IPTG (0.1pM) and X-gal (50ig/ml) and incubated overnight at 37 'C. Single white colonies 5 were chosen for plasmid isolation. 7.2.1.4 Plasmid DNA preparation, restriction digestion and sequence analysis. Miniprep plasmid DNA was prepared from 5 ml cultures using a Biorobot 8000 robotic system (Qiagen) according to the manufacturer's instructions. Plasmid DNA was eluted in 80 ptl sterile water. The DNA concentration was measured using an 10 Eppendorf BO photometer or Spectramax 190 photometer (Molecular Devices). Aliquots of miniprep plasmid DNAs (100-200ng) were digested with EcoRI for 2h at 37 'C and analysed by electrophoresis in 0.8% agarose gels. Plasmids with inserts of the expected size of about 1.1kb were selected for DNA sequence analysis. Inserts were sequenced from either end by mixing 200-500 ng plasmid DNA with the either 15 the T7 or T3 sequencing primers (see Table 4). Sequencing reactions were processed using the BigDye Terminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. Products were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) and analyzed on an Applied Biosystems 3700 sequencer. 20 7.2.1.5 Results of cloning and sequence analysis of nucleotides 678-1740. The predicted mRNA coding sequence for the region spanning the internal BamHI site to the TM domain was confirmed. The DNA miniprep #14 was taken as a representative clone for further work. 7.2.2 Stage 2: Cloning of nucleotides 1-683 25 7.2.2.1 cDNA synthesis In the second stage of cloning, a gene specific cDNA primer for INSP169 (AS515) located immediately downstream of the internal BamlI site, was pooled with gene specific cDNA primers for 6 other predictions, each at a final concentration of 1pM. The pooled cDNA primer set was diluted 10 fold into 40pl of a mixutre containing 1 WO 2006/051333 PCT/GB2005/004390 93 x RT buffer, 500pM each dNTPs, 1 OU/l RNAguard (Pharmacia) and 1 pg denatured polyA+ RNA prepared as described above. cDNA synthesis was initiated by addition of 1OU Omniscript reverse transcriptase (Qiagen) and allowed to proceed for Ih at 37 'C. At the end of the reaction, 5pl of the cDNA mix was used for PCR amplification 5 as described below. 7.2.2.2 PCR amplification for INSP169 nucleotides 1-683 Top strand (AS516) and bottom strand (AS517) PCR primers (see Table 4) were designed to span the predicted coding sequence between the initiator methionine and the internal BamHI site. A BamHI restriction site was added at the 5' end of AS516. 10 A reaction mixture was set up containing 1 x PCR buffer, 0.2mM each dNTP, 0.5pM each PCR primer, 5pl cDNA above, and the PCR reaction was initiated by addition of 5U PfuTurbo (Stratagene). Cycling conditions for 'touchdown' PCR were: 94 'C 2 mi (I cycle); 94 'C 30 sec, 64 'C (decreasing by 1 'C each cycle) 30 sec, 72 'C 80 sec (14 cycles); 94'C 30 sec, 50 'C 30 sec, 72 'C 80 sec (25 cycles); 72 'C 7 min (1 15 cycle). An aliquot of the PCR reaction was analysed by electrophoresis in a 0.8% agarose gel and the remainder was purified using the Wizard PCR Cleanup System (Promega) as recommended by the manufacturer, prior to subcloning of the PCR products. 7.2.2.3 Subcloning PCR products 20 An aliquot of the purified PCR reation was digested with BamHI (New England Biolabs) for 2h at 37 0 C using the enzyme buffer supplied by the manufacturer. In parallel, an appropriate amount of the Bluescript BSK~ cloning vector was digested with BamHI and dephosphorylated using calf intestinal alkaline phosphatase (Roche Diagnostics) according to the supplier's recommendations. The full length linearized 25 and dephosphorylated cloning vector was separated on a 0.8% agarose gel, excised and purified using the Wizard Cleanup System (Promega) according to the protocol provided by the manufacturer. The purified vector DNA and PCR products were mixed in a molar ratio of 1:3 and precipitated overnight at -20 'C in the presence of 2.5 volumes ethanol. The precipitated DNA was recovered by centrifugation, washed 30 in 70% ethanol, dried under vacuum and ligated in a final volume of 10pl using the WO 2006/051333 PCT/GB2005/004390 94 Rapid Ligation Kit (Roche Diagnostics) according to the protocol supplied by the manufacturers. The ligation mixture was then used to transform E. coli strain JM 101 as follows: 50 ptl aliquots of competent JM101 cells were thawed on ice and 1 pl or 5pl of the ligation 5 mixture was added. The cells were incubated for 40 min on ice and then heat shocked by incubation at 42 'C for 2min. 1ml of warm (room temperature) L-Broth (LB) was added and samples were incubated for a further 1 h at 37 'C. The transformation mixture was then plated on LB plates containing ampicillin (100 pIg/ml) IPTG (0.1 p.M) and X-gal (50tg/ml) and incubated overnight at 37 'C. Single white colonies 10 were chosen for plasmid isolation. 7.2.2.4 Plasmid DNA preparation, restriction digestion and sequence analysis. Miniprep plasmid DNA was prepared from 5 ml cultures using a Biorobot 8000 robotic system (Qiagen) according to the manufacturer's instructions. Plasmid DNA was eluted in 80 pl sterile water. The DNA concentration was measured using an 15 Eppendorf BO photometer or Spectramax 190 photometer (Molecular Devices). Aliquots of miniprep plasmid DNAs (100-200ng) were digested with BamHI for 2h at 37 'C and analysed by electrophoresis in 0.8% agarose gels. Plasmids with inserts of the expected size of about 0.7kb were selected for DNA sequence analysis. Inserts were sequenced from either end by mixing 200-500 ng plasmid DNA with the either 20 the T7 or T3 sequencing primers (see Table 4). Sequencing reactions were processed using the BigDye Terminator system (Applied Biosystems cat. no. 4390246) according to the manufacturer's instructions. Products were purified using Dye-Ex columns (Qiagen) or Montage SEQ 96 cleanup plates (Millipore cat. no. LSKS09624) and analyzed on an Applied Biosystems 3700 sequencer. 25 7.2.2.5 Results of cloning and sequence analysis of nucleotides 1-683 The predicted mRNA coding sequence for the region between the initiator methionine and the internal BamHI site was confirmed. The DNA miniprep #15 was taken as a representative clone for further work.
WO 2006/051333 PCT/GB2005/004390 95 7.3 Assembly of the complete INSP169 extracellular domain Aliquots of the DNA miniprep #14 from stage 1 and DNA miniprep#15 from stage 2 were digested with BamHI (New England Biolabs) for 2h at 37 'C using the enzyme buffer supplied by the manufacturer. The full-length, linearized plasmid from 5 miniprep#14 and the 0.7kb excised fragment from miniprep#15 were separated on 0.8% agarose gel, excised and purified using the Wizard Cleanup System (Promega) according to the protocol provided by the manufacturer. The two purified DNAs were mixed in a molar ratio of 1:3 respectively, and precipitated overnight at -20 'C in the presence of 2.5 volumes ethanol. The precipitated DNA was recovered by 10 centrifugation, washed in 70% ethanol, dried under vacuum and ligated in a final volume of 10pl using the Rapid Ligation Kit (Roche Diagnostics) according to the protocol supplied by the manufacturers. Transformation of competent JM1Olwith aliquots of the ligation mix, plasmid isolation and sequence analysis were performed as described in sections 7.2.1.3 and 15 7.2.1.4 above. 7.4 Results of sequence analysis offull length INSP169ec Sequence analysis of 12 miniprep DNAs allowed identification of clones in which the fragment corresponding to nucleotides 1-683 was inserted in the correct orientation upstream of the sequence correponding to nucleotides 678-1740 and in which the 20 junction between the two fragments is the correctly religated BamHl site (position 678-683). DNA miniprep #11 was selected and the complete sequence was verified using sequencing primers T3, T7, AS515 and AS599 (see Table 4). Compared to the prediction, a single SNP was found, G524A, which results in a codon change from 25 Ser>Asn (underlined in Fig 8).
WO 2006/051333 PCT/GB2005/004390 96 Table 4: Primers used for cloning and sequencing of INSP169ec Oligonucleotide Description DNA Sequence (5'-3') AS502 RT primer (in TM) caccacgagaaggagagacc AS503 5' PCR internal primer gcgaattcgctatagtgettctggatcc AS504 3' PCR primer gcgaattetcattgagaatcatctccttcaac AS515 internal RT primer gaggcgctcaggttcactgc AS516 5' PCR primer gcggatccatgcatctctttgcatgtctg AS517 3' PCR internal primer catcagtggatccagaagcac AS599 internal sequencing primer caatccttggttctgtgactg T7 seq primer taatacgactcactatagg T3 seq primer attaaccctcactaaagg
Claims (51)
1. A polypeptide, which polypeptide: (i) comprises the amino acid sequence as recited in SEQ ID NO:2 (mature 5 INSP168); (ii) is a fragment thereof which functions as -a biologically active polypeptide and/or has an antigenic determinant in common with the polypeptides of (i); or (iii) is a functional equivalent of (i) or (ii). 10
2. A polypeptide according to part (i) of claim 1, which polypeptide consists of the amino acid sequence as recited in SEQ ID NO:4 (mature INSP149), SEQ ID NO:6 (INSP149 extracellular region), SEQ ID NO:8 (mature INSP168-SV1), SEQ ID NO:10 (mature INSP169), SEQ ID NO:12 (INSP169 extracellular region) and/or SEQ ID NO:67 (INSP 169 cloned extracellular region). 15
3. A polypeptide which is a functional equivalent according to part (iii) of claim 1, characterised in that it is homologous to the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and/or SEQ ID NO:67.
4. A fragment or functional equivalent according to part (ii) of claim 1, which has 20 greater than 50% sequence identity with the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, and/or SEQ ID NO:67 or with active fragments thereof, preferably greater than 60%, 70%, 80%, 90%, 95%, 98% or 99% sequence identity.
5. A fragment according to claim 4, which consists of the amino acid sequence as 25 recited in SEQ ID NO:14 (LRR motifs).
6. A functional equivalent according to any one of the preceding claims, which exhibits significant structural homology with a polypeptide having the amino acid sequence given in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and/or SEQ ID NO:67. 30
7. A fragment as recited in any one of the preceding claims, having an antigenic determinant in common with the polypeptide of part (i) of claim 1 which WO 2006/051333 PCT/GB2005/004390 148 consists of 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more) amino acid residues from the sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, and/or SEQ ID NO:67. 5
8. A fusion protein comprising the polypeptide according to any one of the preceding claims.
9. The polypeptide of claim 8, wherein said polypeptide comprises a histidine tag.
10. The polypeptide of claim 9, whose sequence is recited in SEQ ID NO: 16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26 10 and/or SEQ ID NO:28.
11. The polypeptide of any one of the preceding claims, wherein said polypeptide comprises a signal peptide.
12. The polypeptide of claim 11, whose sequence is recited in SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, 15 SEQ ID NO:42, SEQ ID NO:44 and/or SEQ ID NO:67.
13. A purified nucleic acid molecule which encodes a polypeptide according to any one of the preceding claims.
14. A purified nucleic acid molecule according to claim 13, which comprises or consists of the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, 20 SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43 and/or SEQ ID NO:66. 25
15. A purified nucleic acid molecule according to claim 13 or claim 14 which consists of the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ 30 ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43 and/or SEQ ID NO:66, or is a redundant equivalent or fragment WO 2006/051333 PCT/GB2005/004390 149 thereof.
16. A purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule according any one of claims 13 to 15.
17. A vector comprising a nucleic acid molecule as recited in any one of claims 13 5 16.
18. A host cell transformed with a vector according to claim 17.
19. A ligand which binds specifically to, and which preferably inhibits the cell surface recognition molecule activity of, a polypeptide according to any one of claims 1-12. 10
20. A ligand according to claim 19, which is an antibody.
21. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1-12.
22. A compound according to claim 21 that binds to a polypeptide according to any one of claims 1-12 without inducing any of the biological effects of the 15 polypeptide.
23. A compound according to claim 21 or claim 22, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
24. A polypeptide according to any one of claims 1-12, a nucleic acid molecule according to any one of claims 13-16, a vector according to claim 17, a host cell 20 according to claim 18, a ligand according to claim 19 or claim 20, or a compound according to any one of claims 21-23, for use in therapy or diagnosis of disease.
25. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of 25 claims 1-12, or assessing the activity of a polypeptide according to any one of claims 1-12, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.
26. A method according to claim 25 that is carried out in vitro. 30
27. A method according to claim 25 or claim 26, which comprises the steps of: (a) WO 2006/051333 PCT/GB2005/004390 150 contacting a ligand according to claim 19 or claim 20 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.
28. A method according to claim 25 or claim 26, comprising the steps of: 5 (a) contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 13-16 and the probe; (b) contacting a control sample with said probe under the same conditions 10 used in step a); and (c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease. 15
29. A method according to claim 25 or claim 26, comprising: (a) contacting a sample of nucleic acid from tissue of the patient with a nucleic acid primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 13-16 and the primer; 20 (b) contacting a control sample with said primer under the same conditions used in step a); and (c) amplifying the sampled nucleic acid; and (d) detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the 25 patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.
30. A method according to claim 25 or claim 26 comprising: (a) obtaining a tissue sample from a patient being tested for disease; (b) isolating a nucleic acid molecule according to any one of claims 13-16 30 from said tissue sample; and WO 2006/051333 PCT/GB2005/004390 151 (c) diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.
31. The method of claim 30, further comprising amplifying the nucleic acid 5 molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.
32. The method of either claim 30 or 31, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid probe that hybridises to said nucleic acid molecule under stringent 10 conditions to form a hybrid double-stranded molecule, the hybrid double stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation. 15
33. A method according to any one of claims 25-32, wherein said disease is selected from diseases of the retina, retinal pigment epithelium (RPE), and choroids; ocular neovascularization, ocular inflammation and retinal degenerations; diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal neovascularization, subretinal 20 neovascularization; rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, 25 cystoid macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, retinal artery occlusion, neovascularization due to penetration of the eye or ocular injury, neuropathies; Leber's, idiopathic, drug-induced, optic, and ischemic neropathies; spinal cord injuries, paraplegia, neurodegenerative disorders, disorders of the central nervous system, disorders 30 of the peripheral nervous system, brain injuries, cerebrovascular diseases, Parkinson's disease, corticobasal degeneration, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post- traumatic brain injury, small-vessel cerebrovascular WO 2006/051333 PCT/GB2005/004390 152 disease, dementias, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinsonism, frontotemporal dementias, Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV 5 dementia, schizophrenia with dementia, Korsakoffs psychosis, stroke and trauma.
34. Use of a polypeptide according to any one of claims 1-12 as a cell surface recognition molecule or as an antagonist of a cell surface recognition molecule.
35. A pharmaceutical composition comprising a polypeptide according to any one 10 of claims 1-12, a nucleic acid molecule according to any one of claims 13-16, a vector according to claim 17, a host cell according to claim 18, a ligand according to claim 19 or 20, or a compound according to any one of claims 21 23.
36. A vaccine composition comprising a polypeptide according to any one of claims 15 1-12 or a nucleic acid molecule according to any one of claims 13-16.
37. A polypeptide according to any one of claims 1-12, a nucleic acid molecule according to any one of claims 13-16, a vector according to claim 17, a host cell according to claim 18, a ligand according to claim 19 or 20, a compound according to any one of claims 21-23, or a pharmaceutical composition 20 according to claim 35, for use in the manufacture of a medicament for the treatment of a disease selected from diseases of the retina, retinal pigment epithelium (RPE), and choroids; ocular neovascularization, ocular inflammation and retinal degenerations; diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, senile macular degeneration, retinal 25 neovascularization, subretinal neovascularization; rubeosis iritis inflammatory diseases, chronic posterior and pan uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma; neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the 30 optic nerve, diabetic macular edema, cystoid macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streak, retinal artery occlusion, neovascularization due to penetration of the eye WO 2006/051333 PCT/GB2005/004390 153 or ocular injury, neuropathies; Leber's, idiopathic, drug-induced, optic, and ischemic neropathies; spinal cord injuries, paraplegia, neurodegenerative disorders, disorders of the central nervous system, disorders of the peripheral nervous system, brain injuries, cerebrovascular diseases, Parkinson's disease, 5 corticobasal degeneration, motor neuron disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, traumatic brain injury, stroke, post-stroke, post traumatic brain injury, small-vessel cerebrovascular disease, dementias, Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinsonism, frontotemporal dementias, Pick's 10 disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, Korsakoffs psychosis, stroke and trauma.
38. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claims 1-12, a nucleic acid 15 molecule according to any one of claims 13-16, a vector according to claim 17, a host cell according to claim 18, a ligand according to claim 19 or 20, or a compound according to any one of claims 21-23, or a pharmaceutical composition according to claim 35.
39. A method according to claim 38, wherein, for diseases in which the expression 20 of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.
40. A method according to claim 38, wherein, for diseases in which the expression 25 of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.
41. A method of monitoring the therapeutic treatment of disease in a patient, 30 comprising monitoring over a period of time the level of expression or activity of a polypeptide according to any one of claims 1-12, or the level of expression of a nucleic acid molecule according to any one of claims 13-16 in tissue from WO 2006/051333 PCT/GB2005/004390 154 said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.
42. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to 5 any one of claims 1-12, or a nucleic acid molecule according to any one of claims 13-16 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said nucleic acid molecule or polypeptide.
43. A kit useful for diagnosing disease comprising a first container containing a 10 nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 13-16; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease.
44. The kit of claim 43, further comprising a third container holding an agent for 15 digesting unhybridised RNA.
45. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 13-16.
46. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of claims 1-12; and a reagent useful for the detection of a binding 20 reaction between said antibody and said polypeptide.
47. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1-12.
48. A method for screening for a compound effective to treat disease, by contacting 25 a non-human transgenic animal according to claim 47 with a candidate compound and determining the effect of the compound on the disease of the animal.
49. A method according to any one of claims 38-44 or claim 48, wherein said disease is one of the diseases set forth in claim 33. 30
50. The use of an INSP168, INSP168-SV1, INSP149 or INSP169 polypeptide as a target for screening candidate drugs for treating or preventing a disorder in WO 2006/051333 PCT/GB2005/004390 155 which leucine-rich repeat (LRR) motif containing proteins are implicated.
51. Method of selecting biologically active compounds comprising: (i) contacting a candidate compound with recombinant host cells expressing an INSP168, INSP168-SV1, INSP149 or INSP169 polypeptide; 5 (ii) selecting compounds that bind said INSP168, INSP168-SV1, INSP149 or INSP 169 polypeptide at the surface of said cells and/or that modulate the activity of the INSP168, INSP168-SV1, INSP149 or INSP169 polypeptide.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0425197A GB0425197D0 (en) | 2004-11-15 | 2004-11-15 | Leucine-rich repeat (LRR) motif containing proteins |
GB0425197.1 | 2004-11-15 | ||
PCT/GB2005/004390 WO2006051333A2 (en) | 2004-11-15 | 2005-11-15 | Leucine-rich repeat (lrr) motif containing proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2005303536A1 true AU2005303536A1 (en) | 2006-05-18 |
Family
ID=33523767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005303536A Abandoned AU2005303536A1 (en) | 2004-11-15 | 2005-11-15 | Leucine-rich repeat (LRR) motif containing proteins |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1814903A2 (en) |
JP (1) | JP2008519593A (en) |
AU (1) | AU2005303536A1 (en) |
CA (1) | CA2586486A1 (en) |
GB (1) | GB0425197D0 (en) |
IL (1) | IL182960A0 (en) |
WO (1) | WO2006051333A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116036239B (en) * | 2023-03-28 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | Application of NEP1-40 in preparation of medicine for specifically inhibiting illusion effect |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001128686A (en) * | 1999-11-09 | 2001-05-15 | Tanabe Seiyaku Co Ltd | New protein and gene encoding the same |
AU2002366713A1 (en) * | 2001-12-20 | 2003-07-09 | Incyte Genomics, Inc. | Nucleotide polymorphisms associated with osteoarthritis |
EP1447413A3 (en) * | 2003-02-14 | 2006-01-04 | Research Association for Biotechnology | Full-length human cDNA |
-
2004
- 2004-11-15 GB GB0425197A patent/GB0425197D0/en not_active Ceased
-
2005
- 2005-11-15 AU AU2005303536A patent/AU2005303536A1/en not_active Abandoned
- 2005-11-15 EP EP05803576A patent/EP1814903A2/en not_active Withdrawn
- 2005-11-15 JP JP2007540722A patent/JP2008519593A/en active Pending
- 2005-11-15 WO PCT/GB2005/004390 patent/WO2006051333A2/en not_active Application Discontinuation
- 2005-11-15 CA CA002586486A patent/CA2586486A1/en not_active Abandoned
-
2007
- 2007-05-03 IL IL182960A patent/IL182960A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006051333A2 (en) | 2006-05-18 |
GB0425197D0 (en) | 2004-12-15 |
WO2006051333A3 (en) | 2006-07-20 |
IL182960A0 (en) | 2007-08-19 |
JP2008519593A (en) | 2008-06-12 |
CA2586486A1 (en) | 2006-05-18 |
EP1814903A2 (en) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003229961B2 (en) | Immunoglobulin-domain containing cell surface recognition molecules | |
US20090324562A1 (en) | Defensin Proteins | |
US8222371B2 (en) | vWFA and/or ANT—IG domain containing proteins | |
US20080226640A1 (en) | C1q Related Protein | |
US20080213286A1 (en) | Mam Domain Containing Protein | |
WO2008015380A2 (en) | Integral membrane protein of the pmp-22/emp/mp20/ claudin-like family | |
US20100196349A1 (en) | Reeler domain containing protein | |
US20100048467A1 (en) | Cystine-Knot Fold Cytokine | |
US20090214548A1 (en) | TGR3-Like Protein Receptor | |
AU2005303536A1 (en) | Leucine-rich repeat (LRR) motif containing proteins | |
WO2007049065A2 (en) | Vwfa, collagen and kunitz domain containing protein | |
WO2007049062A2 (en) | Vwfa-domain containing proteins | |
US7514533B2 (en) | TNF-like secreted protein | |
US20060216709A1 (en) | Midkine-like protein | |
US20070264251A1 (en) | C1q Related Protein | |
WO2008012505A2 (en) | Gpi-anchored cell surface glycoprotein | |
US20070148655A1 (en) | Leucine rich repeat containing protein | |
AU2003295100A1 (en) | Midkine-like protein | |
WO2008012503A1 (en) | Homologue of pro4426 | |
WO2004007552A1 (en) | Cytokine receptor | |
WO2007060431A1 (en) | Netrin-like (ntr) domain containing protein | |
WO2007045891A1 (en) | Kunitz domain containing protein | |
WO2007045911A1 (en) | Integral membrane protein | |
WO2008032053A1 (en) | Fhr-4a splicing variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |